EP2938598A1 - Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 - Google Patents

Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1

Info

Publication number
EP2938598A1
EP2938598A1 EP13828996.2A EP13828996A EP2938598A1 EP 2938598 A1 EP2938598 A1 EP 2938598A1 EP 13828996 A EP13828996 A EP 13828996A EP 2938598 A1 EP2938598 A1 EP 2938598A1
Authority
EP
European Patent Office
Prior art keywords
groups
alkyl
compound
heterocyclyl
phthalazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13828996.2A
Other languages
German (de)
French (fr)
Other versions
EP2938598B1 (en
Inventor
Brijesh K. Srivastava
Ranjit C. Desai
Pankaj R Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54198806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2938598(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to PL13828996T priority Critical patent/PL2938598T3/en
Publication of EP2938598A1 publication Critical patent/EP2938598A1/en
Application granted granted Critical
Publication of EP2938598B1 publication Critical patent/EP2938598B1/en
Priority to HRP20170219TT priority patent/HRP20170219T1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds of general formula (1), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
  • the present invention also relates to processes for preparing the novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
  • the present invention is further directed to compounds which cause selective
  • PARP-1 Poly (ADP-ribose) polymerase- 1
  • PARP-1 is a nuclear protein whose zinc finger DNA binding domain localizes PARP- 1 to the site of DNA damage.
  • This NAD dependent enzyme catalyzes poly (ADP-ribosylation) of proteins, involved in the detection and repair of DNA damage. It plays a frontal role in the decision of a cell to live or to die in a stress situation [Senthil kumar B., Rajmohan, et al, Mol. Cell. Biol.
  • the primary structure of the enzyme is highly, conserved in eukaryotes with human enzyme having 92% homology with mouse enzyme at the level of amino acid sequence and a 50 amino acid block showing 100% homology between vertebrates [Virag Laszlo and Szabo Csaba, Pharmacol. Reviews 2002, 54(i), 375-429].
  • Studies on the molecular mechanism of PARP-1 suggests that, it is involved in various DNA related functions including gene amplifications, cell division, differentiation, apoptosis, DNA base excision repair and also effects on telomere length and chromosome stability [d'Add di Fagogna et al., Nature Gen. 1999, 23(70), 76-80].
  • PARP- 1 modulates DNA repair and other processes and can produce long chains of poly (ADP-ribose) within the cell nucleus which is central to its activity [Althaus, F. R.; Richter, C. Mol. Biol, Biochem. Biophys. 1987, 37, 1- 237].
  • Different studies on knock out mouse models report that the deletion of PARP- 1 impairs DNA repair but is not embryonically lethal.
  • Double knock out PARP- 1 and PARP-2 mice die during early embryogenesis, which shows that PARP-2 as the closest homolog of PARP-1 (62% identical in its catalytic domain to PARP-1 ) & plays a major role in the DNA repair during the absence of PARP-1 enzyme [Ratnam Kapil and Law Jenifer A. Clin.
  • PARP inhibitors could be used not only as chemo/radiotherapy sensitizers, but also as single agents to selectively kill cancers which are due to defect in DNA repair, specifically cancers with mutations in the breast cancer-associated gene (BRCA1 and BRCA2).
  • PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues.
  • the activation of PARP may also induce various cell death processes and promotes an inflammatory response associated with multiple organ failure.
  • PARP poly (ADP-ribose) polymerase
  • Novel compounds which are selective PARP-1 inhibitors, their preparation and their use in medicine have also been reported in WO 2002036576, WO 2006039545, WO 2007062413, WO 2004080976, WO 2009093032, WO 2008047082, WO 2001042219, WO 2005066163, WO 2006106326, WO 2008146035, WO 2006021801 , US 20090192156, WO 2012019427, WO 2012071684, WO 2012019426, WO 2012072033, which are incorporated as references in their entirety.
  • X is selected from NH, S and O.
  • Y is selected from CH or N.
  • a and B together represent an optionally substituted, fused aromatic ring
  • R is selected from the group consisting of H, optionally substituted Ci -2 o alkyl, Ci_ 2 o aryl, C(3 -2 o) heterocyclyl, thioamido, ester, acyl, and sulfonyl groups;
  • R Y is selected from H, hydroxyl, amino; R and R Y may together form a spiro C3.7 cycloalkyl or heterocyclyl group;
  • R C1 and R C2 are independently selected from the group consisting of H and C1-4 alkyl;
  • R 1 is selected from H and halo And Het is selected from
  • Y l is selected from CH and N
  • Y 2 is selected from CH and N
  • Y 3 is selected from CH, CF and N
  • w can be N
  • WO 2012 019426 discloses PARP inhibitors of the following general formula (I)
  • a and B are connected together to the carbon atoms to form a cycloalkyl group, heterocyclic group, aryl or heteroaryl group,
  • Each of the ring atoms D or E is independently selected from C or N atoms; when n is 1 , D and E are connected to one another to accomplish 6 ⁇ 10-membered ring X; This specification is incorporated as reference in its entirety.
  • WO 2012 072033 discloses compounds of formula I or II, their isomers, salts, solvates, chemically protected form, and prodrugs:
  • New Gen Therapeutics, Inc has published a patent WO 2012166983 and disclosed tricyclic inhibitors of poly(ADP-ribose)polymerase.
  • Novel compounds having PARP inhibitory activity has been disclosed by Santen Pharmaceutical Co. Ltd. in a patent WO 2013/008872 and the following formula has been disclosed.
  • AstraZeneca AB has published a patent US 8475842 for immediate release pharmaceutical formation of 4-[3-4(cyclopropanecarbonyl-piperazine-l -carbonyl)-4- fluoro-benzyl]-2H-phthalazin-l -one.
  • the present invention describes novel compounds useful as poly (ADP-ribose) polymerase- 1 inhibitors.
  • the compounds are defined by the general formula (I) below.
  • the compounds of the present invention acts by inhibiting PARP l enzyme to prevent the process of DNA repair and induce cell mediated apoptosis.
  • PARP- 1 deficient or inhibited cells are more sensitive to DNA damaging agents ( ⁇ radiation, topoisomerase inhibitors, and alkylating agents).
  • the compounds of the present invention are selective inhibitors of the poly (ADP-ribose) polymerase-! .
  • the main object of the present invention is to provide novel compounds of general formula (I), their stereoisomers, tautomeric forms, their regioisomers, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures and their use in medicine.
  • Another object of the present invention is provided a process for the preparation of novel compounds of general formula (I), their stereoisomers, regioisomers and their tautomeric forms, novel intermediates involved in their synthesis, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
  • Another object of the present invention is to provide a method of treatment of diseases which can be treated or whose symptoms can be reversed with by administering a therapeutically effective & non-toxic amount of the compound of formula (I) or their pharmaceutically acceptable compositions to the mammals.
  • 'A' and 'B' may be independently selected from hydrogen, alkyl or connected together to the carbon atoms to form a cycioalkyi , heterocyclyl , aryl or heteroaryl groups, wherein each of the said cycioalkyi, heterocyclyl, aryl or heteroaryl groups are further substituted independently by one or more substituent groups selected from alkyl , halogen, hydroxyl , alkoxy , cycioalkyi , heterocyclyl , aryl , heteroaryl , -C(0)OR 5 , -OC(0)R 5 , -0(CH 2 ) P C(0)OR 5 , -C(0)R 5 , -NHC(0)R 5 , - NR 6 R 7 , -OC(0)NR 6 R 7 or -C(0)NR 6 R 7 groups.
  • R 2 is selected from substituent groups consisting of hydrogen atom, hydroxyl, alkyl, cycioalkyi, oxo, C(0)OR 5 , -C(0)R 5 , or -C(0)NR 6 R 7 , wherein said alkyl or cycioalkyi group may be further substituted by one or more substituents groups selected from halogen, hydroxyl, alkyl or alkoxy.
  • R 3 and R 4 are each independently selected from the groups such as hydrogen atom, alkyl , hydroxyl, alkoxy, cycioalkyi, - C(0)OR 5 , -OC(0)R s , -0(CH 2 ) p C(0)OR 5 , - C(0)R 5 , -NHC(0)R 5 , -NR 6 R 7 , -OC(0)NR 6 R 7 or -C(0)NR 6 R 7 alternatively, R 3 and R 4 together form an oxo group;
  • Each of ring atoms 'D' and ⁇ ' is independently selected from C or N atoms;
  • 'D' and ⁇ ' are connected to one another to form 5 membered ring 'X', wherein 'X' is selected from the groups such as cycioalkyi, heterocyclyl, heteroaryl, wherein the cycioalkyi, heterocyclyl or heteroaryl groups is further substituted with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycioalkyi, heterocyclyl, aryl or heteroaryl, benzyl, oxo, OR 5 , -C(0)OR 5 , -OC(0)R 5 , -0(CH 2 ) p C(0)OR 5 , C(0)R 5 , S(0) n R 5 , -NHC(0)R 5 , NR 6 R 7 , -OC(0)NR 6 R 7 or -C(ONR 6 R 7 , wherein the alkyl , cycioalkyi, heterocyclyl, aryl
  • Each of R 6 or R 7 at each occurrence are independently selected from the groups consisting of hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups; wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups are each independently further substituted by one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents;
  • R 6 and R 7 are joined together with nitrogen atom to form a heterocyclic ring; wherein said heterocyclic ring contains one or more heteroatoms selected from N, O, S(0)n, furthermore the stated heterocyclic ring is further substituted with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituted substituents;
  • n 0, 1 or 2 and p is 0, 1 or 2.
  • substituents wherever applicable and where substituents are not specifically mentioned includes, but are not limited to the following radicals, alone or in combination with other radicals, hydroxyl, oxo, halo, thio, nitro, amino, alkyl, alkoxy, haloalkyl or haloalkoxy groups.
  • the groups representing the above may further be selected from those described hereinafter.
  • the "aryl” may be selected from phenyl, naphthyl, tetrahydronaphthyl, indenyl, dihydroindenyl, biphenyl groups and each of these groups may be optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyl groups;
  • Heteroaryl or “heteroaromatic” is selected from suitable single or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more hetero atoms selected from O, N or S, more preferably the groups are selected from pyridyl, thienyl, furyl, pyrrolyl, indolinyl, indolyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, purinyl groups, each of these groups may be further optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups;
  • Heterocyclyl may be selected from suitable saturated, partially saturated or unsaturated aromatic or non-aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, more preferably selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2- oxopiperidinyl, 4-oxopiperidinyI, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, 2-oxomorpholinyI, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazo!idinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzopyr
  • radicals described above may be selected from:
  • alkyl used either alone or in combination with other radicals, denotes a linear or branched radical containing one to six carbons, selected from methyl, ethyl, ⁇ -propyl, wo-propyl, «-butyl, sec-butyl, ier/-butyl, amyl, f-amyl, «-pentyI, w-hexyl, and the like;
  • alkoxy used either alone or in combination with other radicals, is selected from groups containing an alkyl radical, as defined above, attached directly to an oxygen atom, more preferably groups selected from methoxy, ethoxy, «-propoxy, « ⁇ -propoxy, n-butoxy, /-butoxy, wo-butoxy, pentyloxy, hexyloxy, and the like;
  • haloalkyl is selected from an alkyl radical, as defined above, suitably substituted with one or more halogens; such as fluoromethyl, difiuoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups;
  • Haloalkoxy is selected from suitable haloalkyl, as defined above, directly attached to an oxygen atom, more preferably groups selected from fluoromethoxy, chloromethoxy, fluoroethoxy, chloroethoxy and the like;
  • alkylthio denotes a straight or branched or cyclic monovalent substituent comprising an alkyl group as defined above, linked through a divalent sulfur atom having a free valence bond from the sulfur atom, more preferably the groups may be selected from methylthio, ethylthio, propylthio;
  • aralkyl represents an aryl group as defined above attached to an alkyl group as described above;
  • Heteroaralkyl and “heterocyclyclakyl” represents heteroaryl and heterocyclyl groups respectively as defined above attached to an alkyl group as defined above.
  • the compounds of formula (I) may optionally be converted to their suitable pharmaceutically acceptable salts by processes as are known in the art.
  • the novel compounds of the present invention can further be , formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known.
  • the compounds of the present invention modulate PARP- 1 receptor and are useful as a therapeutic target for many diseases and especially for the treatment of cancer.
  • the compounds prepared according to present invention include, but are not limited to:
  • Example 1 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one;
  • Example 2 2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l -yl)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole- l ,3(2H,3aH)-dione;
  • Example 3 4-(4-fluoro-3-( l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl) benzyl)phthalazin-l (2H)-one;
  • Example 4 4-(3-(5-(cyclopropanecarbonyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyl)-4-fluorobenzyl)phthalazin-l (2H)-one;
  • Example 5 4-(3-(l-(cyclopropylmethyl)- 1,4,5, 6-tetrahydropyrrolo[3,4-c]pyrazoIe-5- carbonyl)-4-fluorobenzyl)phthalazin- 1 (2H)-one;
  • Example 6 4-(3-(5-(cyclopropylmethyl)octahydropyrroIo[3,4-c]pyrrole-2-carbonyl)- 4-fluorobenzyl)phthalazin-l (2H)-one;
  • Example 7 4-(4-fluoro-3-(5-(2,2,2-trifluoroethyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyI)benzyl)phthalazin- 1 (2H)-one;
  • Example 8 4-(3-(5-(cyclopropylmethyl)- 1 ,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-
  • Example 9 4 ⁇ (3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l(2H)-one hydrochloride;
  • Example 10 4-(4-fluoro-3-(5-(2-((3-fluorophenyl)thio)-2-methylpropanoyl) octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin- l (2H)-one;
  • Example 1 1 2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l -y!methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole- l ,3(2H,3aH)-dione;
  • Example 12 4-(3-(l -(cyclopropanecarbonyl)-l ,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-l (2H)-one;
  • Example 1 3 tert-butyl 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl) benzoyl) hexahydropyrrolo[3,4-c]pyrrole-2( 1 H)-carboxylate;
  • Example 14 4-(4-fluoro-3-(hexahydro-l H-furo[3,4-c]pyrrole-5-carbonyl) benzyl)phthalazin- 1 (2H)-one;
  • Example 15 4-(4-fluoro-3-(octahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl) phthalazin-l(2H)-one;
  • Example 16 4-(4-fluoro-3-(5-(methylsulfonyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin-1 (2H)-one;
  • Example 17 4-(4-fluoro-3-( l -(methylsulfonyl)-l,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole-5-carbonyl)benzyl)phthalazin-l (2H)-one;
  • Example 18 4-(3-(5-benzoyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one;
  • Example 19 4-(3-(5-(2,4-difluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)- 4-fluorobenzyl) phthalazin-1 (2H)-one;
  • Example 20 4-(3-(5,6-dihydro-4H-furo[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl) phthalazin- l (2H)-one;
  • Example 21 4-(4-fluoro-3-(5-methyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl)phthalazin-l(2H)-one;
  • Example 22 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl)benzoyl) tetrahydropyrrolo[3,4-c]pyrrole-l ,3(2H,3aH)-dione;
  • Example 23 4-(4-fluoro-3-(octahydrocyclopenta[c]pyrrole-2-carbonyl)benzyl) phthalazin- 1 (2H)-one;
  • Example 24 4-(4-fluoro-3-(5-(4-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin- l (2H)-one;
  • Example 25 4-(4-fluoro-3-(5-(2-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin- l (2H)-one;
  • Example 26 4-(4-fluoro-3-(5-(2-4-(4-fluoro-3-(5-((6-methoxypyridin-2-yl)methyl) octahydropyrrolo [3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-l(2H)-one;
  • Example 27 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl)benzoyl)-2- methyl tetrahydropyrrolo[3,4-c]pyrrole-l,3(2H,3aH)-dione;
  • Example 28 4-(4-fluoro-3-( l -methyl- 1 , 4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyI)benzyl)phthalazin-l (2H)-one compound with 4-(4-fluoro-3-(2-methyl- 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-l (2H)-one ( 1 :3);
  • Example 29 4-(3-(2,2-dioxido-3,4,5,6-tetrahydro- l H-thieno[3,4-c]pyrrole-5- carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one;
  • Example 30 4-(3-(5,6-dihydro-4H-thieno[3,4-c]pyrroIe-5-carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one;
  • Example 31 4-(4-fluoro-3-( 1 , 2,3,4, 5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyI) benzyl)phthalazin- 1 (2H)-one;
  • Example 32 4-(4-fluoro-3-(5-phenyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl)phthalazin- l (2H)-one;
  • Example 33 4-(4-fluoro-3-(5-methyl- 1 ,2,3,4,5, 6-hexahydropyrrolo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin- l (2H)-one;
  • Example 34 4-(3-((3a ,8bR)-decahydropyrrolo[3,4-a]pyrrolizine-2-carbonyl)-4- fluorobenzyl)phthalazin- 1 (2H)-one;
  • Example 35 4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl)phthalazin- 1 (2H)-one;
  • Example 36 4-(4-fluoro-3-( 1 -methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl) phthalazin- 1 (2H)-one;
  • Example 37 2-((5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l -yl)methyl) benzoyl) .
  • Example 38 4-(3-(5-(difluoromethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl) phthalazin- l (2H)-one;
  • Example 39 4-(4-fluoro-3-((3aR,6aS)-5-oxooctahydrocyclopenta[c]pyrrole-2- carbony l)benzyl) phthalazin- 1 (2H)-one;
  • Example 40 Mixture of 1 & 2 Ethyl 4-(3-(2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)-4-fluorobenzyl)phthalazin- 1 (2H)-one;
  • Example 41 4-(3-(2-ethyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one;
  • Example 42 4-(3-( l -ethyl- l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one;
  • Example 43 4-(4-fluoro-3-(l -isopropyl-l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl) phthalazin- l (2H)-one;
  • Example 44 Mixture of ( 1 & 2 isopropyl ) 4-(4-fluoro-3-(l ,4,5,6-tetrahydropyrrolo
  • Example 45 4-(4-fluoro-3-(2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzy 1) phthalazin- 1 (2H)-one;
  • Example 46 4-(3-((3a ?,6aiS)-5,5-difluorooctahydrocyclopenta[c]pyrrole-2-carbonyl)- 4-fluorobenzyl)phthalazin-l (2H)-one;
  • Example 47 4-(4-fluoro-3-(5-(2-methoxyethyl)octahydropyrroIo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin-1 (2H)-one;
  • Example 48 N-((3aR,6aS)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- 1 -y l)m eth l) benzoyl)octahydrocyclopenta[c]pyrrol-5-yl)cyclopropanecarboxamide;
  • Example 50 4-(4-fluoro-3-(l -methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl) phthalazin- l (2H)-one hydrobromide;
  • Example 5 1 4-(4-fluoro-3-( l -methyI-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyI)benzyl) phthalazin- l (2H)-one hydrochloride;
  • Example 52 4-(4-fluoro-3-( l -methyl- 1 ,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyI) phthalazin- l (2H)-one sulfate;
  • Example 53 4-(4-fluoro-3-(l -methyl- l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyI)benzyl) phthalazin-1 (2H)-one 4-methylbenzenesulfonate;
  • Example 53 4-(4-fluoro-3-( l -methyl- 1 ,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl) phthalazin- l (2H)-one benzenesulfonate;
  • Example 54 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l -yl)methyl)benzoyl)-2- isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-2-ium hydrogensulfate;
  • Example 55 4-(3-(l-cyclopropyl- l ,4,5,6-tetrahydropyrrolo [3,4-c]pyrazole-5- carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one;
  • Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.
  • the compounds of the present invention may be prepared using the methods described below, together with conventional techniques known to those skilled in the art of organic synthesis, or variations thereon as appreciated by those skilled in the art. Referred methods include, but are not limited to those described below, where all symbols are as defined earlier.
  • Compounds of the general formula (I) can be synthesized by coupling the compounds of the general formula (III) with the compounds of the general formula (II), using suitable coupling agents such as 0-(Benzotriazol-l -yl)-N,N,N',N'- tetramethyluronium-tetrafluoroborate(TBTU),dimethylaminopyridine(DMAP), dicyclohexylcarbodiimide (DCC), hydroxybenzotriazole (HOBt.H 2 0), and l -Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.
  • suitable coupling agents such as 0-(Benzotriazol-l -yl)-N,N,N',N'- tetramethyluronium-tetrafluoroborate(TBTU),dimethylaminopyridine(DMAP), dicyclohexylcarbodiimide (DCC),
  • HC1 & the like in the presence of organic bases such as DIPEA, TEA, pyridine, & the like in the solvents such as tetrahydrofuran, dimethyl formamide, dichloromethane, chloroform & the like or their suitable mixtures at ambient temperature.
  • organic bases such as DIPEA, TEA, pyridine, & the like in the solvents such as tetrahydrofuran, dimethyl formamide, dichloromethane, chloroform & the like or their suitable mixtures at ambient temperature.
  • reaction mixture was diluted with ethyl acetate.
  • the organic layer was washed with water, dried over anhydrous Na 2 S0 4 and solvents were evaporated on a rotatory evaporator under reduced pressure to crude solid which was purified by the flash column chromatography using eluent chloroform : methanol (97 : 3) to afford 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl) phthalazin- l (2H)-one as white solid ( 1.19 g, 74 %).
  • MMS Methyl Methane Sulphonate
  • the compounds were tested for PARP- 1 inhibitory activity by using HT universal colorimetric PARP assay kit obtained from Trevigen, following manufacturer's protocol.
  • mice Female athymic nude mice were used for antitumor in vivo studies.
  • SW620 colorectal tumor cells (1 x 10 7 cells per animal) were implanted s.c. into one flank of each mouse.
  • Tumor growths were measured using two-dimensional caliper measurements. Tumor volume was calculated using the equation a 2 x b / 2, where a is the smallest measurement and b is the largest.
  • RTV median relative tumor volumes
  • TTD tumor growth delay
  • PARP 1 IC 50 are estimation as calculated from a 4 point dose response curve
  • Table 2 In vivo antitumor efficacy of compounds in combination with temozolomide (T Z) in an SW620 tumor model b .
  • mice were orally dosed once daily for 5 consecutive days. The compounds were administered 45 min before TMZ.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis. The compounds of formula (I) are useful as PARP-1 inhibitors for the treatment of, e.g. cancer.

Description

SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1
FIELD OF THE INVENTION
The present invention relates to novel compounds of general formula (1), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to processes for preparing the novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
The present invention is further directed to compounds which cause selective
inhibition of the poly (ADP-ribose) polymerase- 1.
BACKGROUND & PRIOR ART
Exploitation of synthetic lethal relationship is a trustworthy therapeutic strategy to target genetic differences between tumor and normal cells which eventually provide large therapeutic window for the treatment of cancer. Poly (ADP-ribose) polymerase- 1 (PARP- 1, 1 13 kDa) is a prototype member of the 17 member PARP protein superfamily. PARP-1 is a nuclear protein whose zinc finger DNA binding domain localizes PARP- 1 to the site of DNA damage. This NAD dependent enzyme catalyzes poly (ADP-ribosylation) of proteins, involved in the detection and repair of DNA damage. It plays a frontal role in the decision of a cell to live or to die in a stress situation [Senthil kumar B., Rajmohan, et al, Mol. Cell. Biol. 2009, 29(15), 41 16- 4129]. The primary structure of the enzyme is highly, conserved in eukaryotes with human enzyme having 92% homology with mouse enzyme at the level of amino acid sequence and a 50 amino acid block showing 100% homology between vertebrates [Virag Laszlo and Szabo Csaba, Pharmacol. Reviews 2002, 54(i), 375-429]. Studies on the molecular mechanism of PARP-1 suggests that, it is involved in various DNA related functions including gene amplifications, cell division, differentiation, apoptosis, DNA base excision repair and also effects on telomere length and chromosome stability [d'Add di Fagogna et al., Nature Gen. 1999, 23(70), 76-80]. It has been reported that PARP- 1 modulates DNA repair and other processes and can produce long chains of poly (ADP-ribose) within the cell nucleus which is central to its activity [Althaus, F. R.; Richter, C. Mol. Biol, Biochem. Biophys. 1987, 37, 1- 237]. Different studies on knock out mouse models, report that the deletion of PARP- 1 impairs DNA repair but is not embryonically lethal. Double knock out PARP- 1 and PARP-2 mice die during early embryogenesis, which shows that PARP-2 as the closest homolog of PARP-1 (62% identical in its catalytic domain to PARP-1 ) & plays a major role in the DNA repair during the absence of PARP-1 enzyme [Ratnam Kapil and Law Jenifer A. Clin. Cancer Res. 2007, \ 1(5), 1383- 1388]. A group of scientists from Newcastle University and University of Konstanz, in British Journal of Cancer 2009, 101(2), 256 - 26, claims to be the first to directly compare PARP-1 polymorphisms, cellular levels of PARP- 1 protein and PARP activity in a systematic way and reveals that PARP activity depends on other factors beside the level of protein and the active site SNP.
In a recent review from Free Radical Biology & Medicine 2009, 47, 13-26 suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers, but also as single agents to selectively kill cancers which are due to defect in DNA repair, specifically cancers with mutations in the breast cancer-associated gene (BRCA1 and BRCA2). PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues. The activation of PARP may also induce various cell death processes and promotes an inflammatory response associated with multiple organ failure.
Recently some of the investigators have demonstrated in Biochem. Pharmacol. 2009, 77, 1348-1357 that PARP inhibitors combined with DNA-damage inducing cytostatic agents like taxol can lead to effective tumor therapy through activation of Pl-3-kinase- Akt pathway.
The American Society of Clinical Oncology held its Annual Meeting in Orlando, Florida (May 29-June 2, 2009) and as reported in Eur. J. Cancer 2009, 45, 1897 - 1901 that two drugs Olaparib and BS1-201 from a new class of targeted agents called poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated significant activity against hard-to treat breast cancers, according to findings from two separate phase 11 trials.
Several small molecules that specifically target PARP-1 enzyme as an inhibitor are being investigated and among them BSI 201 (BiPar) is in Phase ill clinical trial and AG 14699 (Cancer Res. UK), AZD 2281 (KuDOS), ABT 888 (Abbott) are in Phase II clinical trial, with promising initial results. However, special attention must be paid to the possibility that enhanced therapeutic efficacy might be accompanied by increased off-target effects because of effect on DNA-repair mechanism in normal tissues. Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets as described in Nature Reviews Cancer 4 March 2010, 1-9. Crystal Structure of the Catalytic Domain of Human PARP2 in Complex with PARP Inhibitor ABT-888 repoted by [Herwig Schuler et al, Pharmacol. Biochemistry 2010, 49, 1056-1058]
Novel compounds which are selective PARP-1 inhibitors, their preparation and their use in medicine have also been reported in WO 2002036576, WO 2006039545, WO 2007062413, WO 2004080976, WO 2009093032, WO 2008047082, WO 2001042219, WO 2005066163, WO 2006106326, WO 2008146035, WO 2006021801 , US 20090192156, WO 2012019427, WO 2012071684, WO 2012019426, WO 2012072033, which are incorporated as references in their entirety. Synthesis of pthalazinone derivatives of the following general formula and having the potential to inhibit PARP for the treatment of cancer or for potentiating tumor cells for the treatment with ionizing radiation or chemotherapeutic agents has been disclosed in US 2009/0192156 A l and WO 2009/093032 A l .
Synthesis of thiophene carboxamide class of compounds as the combination of CH and PARP inhibitors for the treatment of cancer is disclosed in WO 2008146035 Al and WO 2005066163 A2. Representative compounds have the following general formula,
Wherein X is selected from NH, S and O. Y is selected from CH or N.
Crystalline form and improved method for the synthesis of particular pthalazinone derivatives and use of the crystalline form as PARP-1 inhibitor has been reported in WO 2008047082. Representative compounds have the following structure:
Synthesis of 4-heteroaryl methyl substituted pthalazinone derivatives has been disclosed in WO 2006021801 A l and WO 2004080976 A l for use in treating cancer or other diseases ameliorated by the inhibition of PARP.
wherein, A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; If X= NRX then n is 1 or 2 and if X= CRXRY then n is 1 ; R is selected from the group consisting of H, optionally substituted Ci-2o alkyl, Ci_2o aryl, C(3-2o) heterocyclyl, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxyl, amino; R and RY may together form a spiro C3.7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of H and C1-4 alkyl; R1 is selected from H and halo And Het is selected from
where Yl is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, w can be N; and
wherein Q is O or S.
Optimization of Phenyl-Substituted Benzimidazole Carboxamide Poly(ADP-Ribose) 5-Benzamidoisoquinolin-l-ones and 5-((o-Carboxyalkyi)isoquinolin-l-ones as Isoform-Selective Inhibitors of Poly(ADP-ribose) Polymerase 2 (PARP-2) has been described in J. Med. Chem. 2011, 54, 2049-2059 by Peter T. Sunderland et. al.
Tumor Growth Inhibition by Olaparib in BRCA2 Germ line-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts has been recently published in Clin Cancer Res 2011, 1 7, 783-791.
Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry has been described in Journal of Chromatography B, 2011, 878, 333- 339.
"Evolution of Poly(ADP-ribose)Polymerase-l(PARP-l) inhibitors, From Concept to Clinic" a review article by Dana V. Ferraris has been published in J. Med. Chem. 2010, 53, 4561-4584, which describes in details of the efforts by different pharmaceutical industries and academic institutions in the development of the PARP 1 inhibitors. "Development of substituted6-[4-fluoro-3-(piperazin-l -ylcarbonyl)benzyl]-4,5- dimethylpyridazin-3-(2H)-ones as potent poly(ADP-ribose)polymerase -l (PARP- l ) inhibitors active in BRCA deficient cells " artcle has been published by Federica Ferrigno et al. in Bioorg. Med Chem. Lett. 2010, 20, 1 100-1 105.
'Polymerase Inhibitors: Identification of (S)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)- l H-benzimidazole-4-carboxamide (A-966492), a ighly Potent and Efficacious Inhibitor' has been des 2010, 53, 3142-3153.
Design, synthesis of Quinoline-8-carboxamides, a new class of Poly (adenosine- diphosphate-ribose) polymerase- 1 (PARP-1) Inhibitor has been described in J. Med. Chem. 2009, 52, 868-877. Synthesis of 2-[(/?)-2-methylpyrrolidin-2-yl]-lH- benzimidazole-4-carboxamide as a Poly (ADP-ribose) Polymerase (PARP) Inhibitor has been disclosed in J. Med. Chem. 2009, 52, 514-523.
Synthesis of aminoethyl pyrroio dihydroisoquinolinones as novel poly (ADP-ribose) polymerase- 1 inhibitors has been described in Bioorg. Med. Chem. Lett. 2009, 19, 4042-4045. Representative compounds have the following general formula.
Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase- 1 (PARP- l) inhibitors inhibitors has been described in Bioorg. Med. Chem. Lett. 2009, 19, 7537-7541. Representative compounds have the following general formula.
Identification of substituted pyrazolo[ l ,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-l (PARP- l ) inhibitors has been described in Bioorg. Med. Chem. Lett. 2009, 19, 4196-4200. Representative compounds have the following general formula
Synthesis of novel tricyclic quinoxalinone as the inhibitors of poly (ADP-ribose) polymerase- l (PARP-l ) has been stated in Bioorg. Med. Chem. Lett. 2009, 19, 4050- 4054. Representative compounds have the following general formula.
Identification of ring-fused pyrazolo pyridin-2-ones as novel poly (ADP-ribose) polymerase-l inhibitors has been published in Bioorg. Med. Chem. Lett. 2008, 18, 126-5129. This describes compounds of the following general formula.
Discovery of Orally Active and Brain-Penetrable Quinoxalinone Inhibitors of Poly (ADP-ribose) polymerase has been disclosed in J. Med. Chem. 2004, 47, 415 1 -4154 and describes compounds of the following general formula.
Discovery of potent Poly(ADP-ribose) Polymerase- 1 Inhibitors from the modification of Indeno[l ,2-c]isoquinolinone and the described compounds of the following general formula 1 has been reported in J. Med. Chem. 2005, 48, 5100-5103.
WO 2012 019426 discloses PARP inhibitors of the following general formula (I)
wherein: A and B are connected together to the carbon atoms to form a cycloalkyl group, heterocyclic group, aryl or heteroaryl group, Each of the ring atoms D or E is independently selected from C or N atoms; when n is 1 , D and E are connected to one another to accomplish 6 ~ 10-membered ring X; This specification is incorporated as reference in its entirety.
WO 2012 072033 discloses compounds of formula I or II, their isomers, salts, solvates, chemically protected form, and prodrugs:
II
wherein the substituents are as defined in the specification which is incorporated in entirety as reference.
New Gen Therapeutics, Inc has published a patent WO 2012166983 and disclosed tricyclic inhibitors of poly(ADP-ribose)polymerase.
Substituted 4-(4-fluoro-3-(piperazine-l -carbonyl)benzyl)phthalazin-l (2H)-one derivatives as Poly (ADP-ribose) polymerase- 1 inhibitors has been published in WO 2012014221 by Cadila Healthcare Ltd. and discloses the following general structure
Shanghai Institute of Materia Medica, Chinese Academy of Science disclosed 2- Arylbenzofuran-7-formamide compounds preparation method and use thereof in patent WO 20131 17120 and mentions the following formula:
(I)
Merck disclosed tetrahydro-quinazolinone derivatives as tankyrase and PARP inhibitors in patent WO 2013/1 17288 and mentions the following general structure
Novel compounds having PARP inhibitory activity has been disclosed by Santen Pharmaceutical Co. Ltd. in a patent WO 2013/008872 and the following formula has been disclosed.
(I)
Fused tetra or penta- cyclic pyridophthalazinones as PARP inhibitors have been reported by Belgena, Ltd. in a patent WO 2013097226.
AstraZeneca AB has published a patent US 8475842 for immediate release pharmaceutical formation of 4-[3-4(cyclopropanecarbonyl-piperazine-l -carbonyl)-4- fluoro-benzyl]-2H-phthalazin-l -one.
BioMarin recently published a patent US 2013/0053365 and disclosed the formula (M)
formula (M)
Though several compounds have been reported in the literature as PARP-I inhibitors, very few have actually shown actual clinical benefits and none have been approved so far. Looking at the large unmet medical needs, there appears a need for developing further compounds which have better safety and efficacy profile. We herein disclose a new series of compounds which shows potential as PARP-I inhibitors.
SUMMARY OF THE INVENTION
The present invention describes novel compounds useful as poly (ADP-ribose) polymerase- 1 inhibitors. The compounds are defined by the general formula (I) below.
(I)
The compounds of the present invention acts by inhibiting PARP l enzyme to prevent the process of DNA repair and induce cell mediated apoptosis. As a result of compromised repair, PARP- 1 deficient or inhibited cells are more sensitive to DNA damaging agents (γ radiation, topoisomerase inhibitors, and alkylating agents).The compounds of the present invention are selective inhibitors of the poly (ADP-ribose) polymerase-! .
u OBJECTS OF THE INVENTION
The main object of the present invention is to provide novel compounds of general formula (I), their stereoisomers, tautomeric forms, their regioisomers, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures and their use in medicine.
(I)
Another object of the present invention is provided a process for the preparation of novel compounds of general formula (I), their stereoisomers, regioisomers and their tautomeric forms, novel intermediates involved in their synthesis, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Another object of the present invention is to provide a method of treatment of diseases which can be treated or whose symptoms can be reversed with by administering a therapeutically effective & non-toxic amount of the compound of formula (I) or their pharmaceutically acceptable compositions to the mammals.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the present invention are defined by the general formula (I) below:
(I) wherein 'A' and 'B' may be independently selected from hydrogen, alkyl or connected together to the carbon atoms to form a cycioalkyi , heterocyclyl , aryl or heteroaryl groups, wherein each of the said cycioalkyi, heterocyclyl, aryl or heteroaryl groups are further substituted independently by one or more substituent groups selected from alkyl , halogen, hydroxyl , alkoxy , cycioalkyi , heterocyclyl , aryl , heteroaryl , -C(0)OR5, -OC(0)R5, -0(CH2)PC(0)OR5, -C(0)R5, -NHC(0)R5, - NR6R7, -OC(0)NR6R7 or -C(0)NR6R7 groups.
R1 at each occurrence is independently selected from H, halogen, or the groups selected from (Ci -C i 2)alkyl, haloalkyl, cycioalkyi, alkylthio or the group (OS02) alkyl, wherein each of these groups may be further substituted by suitable substituents selected from those disclosed hereinafter below; m = 1 -4;
L= -O, -S, -NH;
R2 is selected from substituent groups consisting of hydrogen atom, hydroxyl, alkyl, cycioalkyi, oxo, C(0)OR5, -C(0)R5, or -C(0)NR6R7, wherein said alkyl or cycioalkyi group may be further substituted by one or more substituents groups selected from halogen, hydroxyl, alkyl or alkoxy.
R3 and R4 are each independently selected from the groups such as hydrogen atom, alkyl , hydroxyl, alkoxy, cycioalkyi, - C(0)OR5, -OC(0)Rs, -0(CH2)pC(0)OR5, - C(0)R5, -NHC(0)R5, -NR6R7, -OC(0)NR6R7 or -C(0)NR6R7 alternatively, R3 and R4 together form an oxo group;
Each of ring atoms 'D' and Έ' is independently selected from C or N atoms;
'D' and Έ' are connected to one another to form 5 membered ring 'X', wherein 'X' is selected from the groups such as cycioalkyi, heterocyclyl, heteroaryl, wherein the cycioalkyi, heterocyclyl or heteroaryl groups is further substituted with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycioalkyi, heterocyclyl, aryl or heteroaryl, benzyl, oxo, OR5, -C(0)OR5, -OC(0)R5, -0(CH2)pC(0)OR5, C(0)R5, S(0)nR5, -NHC(0)R5, NR6R7, -OC(0)NR6R7 or -C(ONR6R7, wherein the alkyl , cycioalkyi, heterocyclyl, aryl, heteroaryl or benzyl are each independently substituted further with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycioalkyi, heterocyclyl, aryl, heteroaryl, oxo,- C(0)OR5, - OC(0)R5, 0(CH2)pC(0)OR5, -C(0)R5, -S(0)nR5„ -NHC(0)R5, NR6R7, - OC(0)NR6R7 or -C(0)NR6R7 substituents; R5 at each occurrence is independently selected from hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups; wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups are each independently substituted by one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents. Each of R6 or R7 at each occurrence are independently selected from the groups consisting of hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups; wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups are each independently further substituted by one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents;
Alternatively, R6 and R7 are joined together with nitrogen atom to form a heterocyclic ring; wherein said heterocyclic ring contains one or more heteroatoms selected from N, O, S(0)n, furthermore the stated heterocyclic ring is further substituted with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituted substituents;
n is 0, 1 or 2 and p is 0, 1 or 2.
Suitable substituents wherever applicable and where substituents are not specifically mentioned includes, but are not limited to the following radicals, alone or in combination with other radicals, hydroxyl, oxo, halo, thio, nitro, amino, alkyl, alkoxy, haloalkyl or haloalkoxy groups.
The preferred heterocycles representing
may be selected from the following bicyclic rings mentioned below
In another preferred embodiment, the groups representing the above may further be selected from those described hereinafter.
The "aryl" may be selected from phenyl, naphthyl, tetrahydronaphthyl, indenyl, dihydroindenyl, biphenyl groups and each of these groups may be optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyl groups;
"Heteroaryl" or "heteroaromatic" is selected from suitable single or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more hetero atoms selected from O, N or S, more preferably the groups are selected from pyridyl, thienyl, furyl, pyrrolyl, indolinyl, indolyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, purinyl groups, each of these groups may be further optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups;
"Heterocyclyl" may be selected from suitable saturated, partially saturated or unsaturated aromatic or non-aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, more preferably selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2- oxopiperidinyl, 4-oxopiperidinyI, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, 2-oxomorpholinyI, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazo!idinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuranyi, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinoyl, thienopyrimidonyl, quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thienopiperidinyl groups, each of these groups may be optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxy!, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups;
In a further embodiment the groups, radicals described above may be selected from:
- the term"alkyl" used either alone or in combination with other radicals, denotes a linear or branched radical containing one to six carbons, selected from methyl, ethyl, ^-propyl, wo-propyl, «-butyl, sec-butyl, ier/-butyl, amyl, f-amyl, «-pentyI, w-hexyl, and the like;
- the term"alkoxy" used either alone or in combination with other radicals, is selected from groups containing an alkyl radical, as defined above, attached directly to an oxygen atom, more preferably groups selected from methoxy, ethoxy, «-propoxy, «ο-propoxy, n-butoxy, /-butoxy, wo-butoxy, pentyloxy, hexyloxy, and the like;
- the term"haloalkyl" is selected from an alkyl radical, as defined above, suitably substituted with one or more halogens; such as fluoromethyl, difiuoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups;
- "Haloalkoxy" is selected from suitable haloalkyl, as defined above, directly attached to an oxygen atom, more preferably groups selected from fluoromethoxy, chloromethoxy, fluoroethoxy, chloroethoxy and the like;
- the term"a!kylthio" used either alone or in combination with other radicals, denotes a straight or branched or cyclic monovalent substituent comprising an alkyl group as defined above, linked through a divalent sulfur atom having a free valence bond from the sulfur atom, more preferably the groups may be selected from methylthio, ethylthio, propylthio;
- the term "aralkyl" represents an aryl group as defined above attached to an alkyl group as described above;
- "Heteroaralkyl" and "heterocyclyclakyl" represents heteroaryl and heterocyclyl groups respectively as defined above attached to an alkyl group as defined above. The compounds of formula (I) may optionally be converted to their suitable pharmaceutically acceptable salts by processes as are known in the art. The novel compounds of the present invention can further be , formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known.
The compounds of the present invention modulate PARP- 1 receptor and are useful as a therapeutic target for many diseases and especially for the treatment of cancer. The compounds prepared according to present invention include, but are not limited to:
Example 1 : 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one;
Example 2: 2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l -yl)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole- l ,3(2H,3aH)-dione;
Example 3: 4-(4-fluoro-3-( l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl) benzyl)phthalazin-l (2H)-one;
Example 4: 4-(3-(5-(cyclopropanecarbonyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyl)-4-fluorobenzyl)phthalazin-l (2H)-one;
Example 5: 4-(3-(l-(cyclopropylmethyl)- 1,4,5, 6-tetrahydropyrrolo[3,4-c]pyrazoIe-5- carbonyl)-4-fluorobenzyl)phthalazin- 1 (2H)-one;
Example 6: 4-(3-(5-(cyclopropylmethyl)octahydropyrroIo[3,4-c]pyrrole-2-carbonyl)- 4-fluorobenzyl)phthalazin-l (2H)-one;
Example 7: 4-(4-fluoro-3-(5-(2,2,2-trifluoroethyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyI)benzyl)phthalazin- 1 (2H)-one;
Example 8: 4-(3-(5-(cyclopropylmethyl)- 1 ,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-
2-carbonyl)-4-fluorobenzyl)phthalazin- l (2H)-one;
Example 9: 4^(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l(2H)-one hydrochloride;
Example 10: 4-(4-fluoro-3-(5-(2-((3-fluorophenyl)thio)-2-methylpropanoyl) octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin- l (2H)-one;
Example 1 1 : 2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l -y!)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole- l ,3(2H,3aH)-dione; Example 12: 4-(3-(l -(cyclopropanecarbonyl)-l ,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-l (2H)-one;
Example 1 3: tert-butyl 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl) benzoyl) hexahydropyrrolo[3,4-c]pyrrole-2( 1 H)-carboxylate;
Example 14: 4-(4-fluoro-3-(hexahydro-l H-furo[3,4-c]pyrrole-5-carbonyl) benzyl)phthalazin- 1 (2H)-one;
Example 15: 4-(4-fluoro-3-(octahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl) phthalazin-l(2H)-one;
Example 16: 4-(4-fluoro-3-(5-(methylsulfonyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin-1 (2H)-one;
Example 17: 4-(4-fluoro-3-( l -(methylsulfonyl)-l,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole-5-carbonyl)benzyl)phthalazin-l (2H)-one;
Example 18: 4-(3-(5-benzoyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one;
Example 19: 4-(3-(5-(2,4-difluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)- 4-fluorobenzyl) phthalazin-1 (2H)-one;
Example 20: 4-(3-(5,6-dihydro-4H-furo[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl) phthalazin- l (2H)-one;
Example 21 : 4-(4-fluoro-3-(5-methyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl)phthalazin-l(2H)-one;
Example 22: 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl)benzoyl) tetrahydropyrrolo[3,4-c]pyrrole-l ,3(2H,3aH)-dione;
Example 23: 4-(4-fluoro-3-(octahydrocyclopenta[c]pyrrole-2-carbonyl)benzyl) phthalazin- 1 (2H)-one;
Example 24: 4-(4-fluoro-3-(5-(4-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin- l (2H)-one;
Example 25: 4-(4-fluoro-3-(5-(2-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin- l (2H)-one;
Example 26: 4-(4-fluoro-3-(5-(2-4-(4-fluoro-3-(5-((6-methoxypyridin-2-yl)methyl) octahydropyrrolo [3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-l(2H)-one;
Example 27: 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl)benzoyl)-2- methyl tetrahydropyrrolo[3,4-c]pyrrole-l,3(2H,3aH)-dione; Example 28: 4-(4-fluoro-3-( l -methyl- 1 , 4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyI)benzyl)phthalazin-l (2H)-one compound with 4-(4-fluoro-3-(2-methyl- 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-l (2H)-one ( 1 :3);
Example 29: 4-(3-(2,2-dioxido-3,4,5,6-tetrahydro- l H-thieno[3,4-c]pyrrole-5- carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one;
Example 30: 4-(3-(5,6-dihydro-4H-thieno[3,4-c]pyrroIe-5-carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one;
Example 31 : 4-(4-fluoro-3-( 1 , 2,3,4, 5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyI) benzyl)phthalazin- 1 (2H)-one;
Example 32: 4-(4-fluoro-3-(5-phenyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl)phthalazin- l (2H)-one;
Example 33: 4-(4-fluoro-3-(5-methyl- 1 ,2,3,4,5, 6-hexahydropyrrolo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin- l (2H)-one;
Example 34: 4-(3-((3a ,8bR)-decahydropyrrolo[3,4-a]pyrrolizine-2-carbonyl)-4- fluorobenzyl)phthalazin- 1 (2H)-one;
Example 35: 4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl)phthalazin- 1 (2H)-one;
Example 36: 4-(4-fluoro-3-( 1 -methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl) phthalazin- 1 (2H)-one;
Example 37: 2-((5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l -yl)methyl) benzoyl) . hexahydropyrrolo [3,4-c]pyrrol-2( l H)-yl)methyI)-6-methoxypyridine-l -oxide;
Example 38: 4-(3-(5-(difluoromethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl) phthalazin- l (2H)-one;
Example 39: 4-(4-fluoro-3-((3aR,6aS)-5-oxooctahydrocyclopenta[c]pyrrole-2- carbony l)benzyl) phthalazin- 1 (2H)-one;
Example 40: Mixture of 1 & 2 Ethyl 4-(3-(2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)-4-fluorobenzyl)phthalazin- 1 (2H)-one;
Example 41 : 4-(3-(2-ethyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one;
Example 42: 4-(3-( l -ethyl- l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one; Example 43: 4-(4-fluoro-3-(l -isopropyl-l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl) phthalazin- l (2H)-one;
Example 44: Mixture of ( 1 & 2 isopropyl ) 4-(4-fluoro-3-(l ,4,5,6-tetrahydropyrrolo
[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin- 1 (2H)-one;
Example 45: 4-(4-fluoro-3-(2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzy 1) phthalazin- 1 (2H)-one;
Example 46: 4-(3-((3a ?,6aiS)-5,5-difluorooctahydrocyclopenta[c]pyrrole-2-carbonyl)- 4-fluorobenzyl)phthalazin-l (2H)-one;
Example 47: 4-(4-fluoro-3-(5-(2-methoxyethyl)octahydropyrroIo[3,4-c]pyrrole-2- carbonyl)benzyl) phthalazin-1 (2H)-one;
Example 48: N-((3aR,6aS)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- 1 -y l)m eth l) benzoyl)octahydrocyclopenta[c]pyrrol-5-yl)cyclopropanecarboxamide;
Example 50: 4-(4-fluoro-3-(l -methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl) phthalazin- l (2H)-one hydrobromide;
Example 5 1 : 4-(4-fluoro-3-( l -methyI-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyI)benzyl) phthalazin- l (2H)-one hydrochloride;
Example 52: 4-(4-fluoro-3-( l -methyl- 1 ,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyI) phthalazin- l (2H)-one sulfate;
Example 53: 4-(4-fluoro-3-(l -methyl- l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyI)benzyl) phthalazin-1 (2H)-one 4-methylbenzenesulfonate;
Example 53: 4-(4-fluoro-3-( l -methyl- 1 ,4, 5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl) phthalazin- l (2H)-one benzenesulfonate;
Example 54: 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l -yl)methyl)benzoyl)-2- isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-2-ium hydrogensulfate;
Example 55: 4-(3-(l-cyclopropyl- l ,4,5,6-tetrahydropyrrolo [3,4-c]pyrazole-5- carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one;
Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.
The compounds of the present invention may be prepared using the methods described below, together with conventional techniques known to those skilled in the art of organic synthesis, or variations thereon as appreciated by those skilled in the art. Referred methods include, but are not limited to those described below, where all symbols are as defined earlier.
The compounds of the present invention can be prepared according to the following schemes 1
Scheme 1:
(II) (III) (I) a Reagents and conditions: , DMF, TBTU, triethylamine, 0-27 °C, 2-6 h
Synthesis of compound of general formula (I)
General process of preparation:
The Compounds of the general formula (II) can be synthesized by processes reported for e.g. in J. Med. Chem. 2008, 51, 6581 -6591 with suitable modifications/alterations as required which are within the skills of a skilled person.
Compounds of the general formula (I) can be synthesized by coupling the compounds of the general formula (III) with the compounds of the general formula (II), using suitable coupling agents such as 0-(Benzotriazol-l -yl)-N,N,N',N'- tetramethyluronium-tetrafluoroborate(TBTU),dimethylaminopyridine(DMAP), dicyclohexylcarbodiimide (DCC), hydroxybenzotriazole (HOBt.H20), and l -Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC. HC1) & the like in the presence of organic bases such as DIPEA, TEA, pyridine, & the like in the solvents such as tetrahydrofuran, dimethyl formamide, dichloromethane, chloroform & the like or their suitable mixtures at ambient temperature.
The invention is further exemplified by the following non-limiting examples which are provided for exemplifying the invention and should not be construed as limiting the scope of the invention in any ways. t will be appreciated that the other embodiments which are not exemplified can be easily practiced by a skilled person using his routine skills after reading the specific examples provided below. Such changes/alterafions/modifications etc. which may be required to practice the full scope of the invention as described and claimed in the present invention are well within the scope of a person skilled in the art.
Unless otherwise specified, 1 H NMR spectral data given in the examples are recorded using a 400 MHz spectrometer (Bruker Topspin 2.0) and reported in δ scale. Tetra methyl si lane is used as the internal standard.
Example 1
Synthesis of 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one.
To a solution of 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl)benzoic acid (1 g, 3.35 mmol) in dry DMF ( 15 mL) was added TBTU (1.292 g, 4.02 mmol) at room temperature under atmosphere of nitrogen. To this 2- benzyloctahydropyrrolo[3,4-c]pyrrole (0.678 g, 3.35 mmol) and DIPEA (1 .32 mL, 6.71 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. The progress of reaction was checked by TLC by using mobile phase 5 % methanol in chloroform. The reaction mixture was diluted with ethyl acetate. The organic layer was washed with water, dried over anhydrous Na2S04 and solvents were evaporated on a rotatory evaporator under reduced pressure to crude solid which was purified by the flash column chromatography using eluent chloroform : methanol (97 : 3) to afford 4-(3-(5-benzyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl) phthalazin- l (2H)-one as white solid ( 1.19 g, 74 %).
'H-NMR (400 MHz, DMSO-i¼) 5 12.59 (s, 1 H), 8.25 (dd, J = 7.6 Hz & 0.6 Hz, 1 H), 7.94 (d, J = 7.6 Hz, 1 H), 7.86 - 7.80 (m, 2H), 7.35 (m, 1 H), 7.32 (dd, 1 H), 5.29 - 7.24 (m, 4H), 7.23 - 7.20 (m, 2H), 4.32 (s, 2H ), 3.63 (m, 1 H), 3.47 (m, 1 H), 3.46 (m, 2H), 3.36 (m, 1 H), 2.9 (dd, 1 H), 2.60 - 2.8 (m, 3H), 2.51 - 2.49 (m, 2H), 2.1 (m, I H). Example 2 2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l-yl)methyl)bi
tetrahydropyrrolo[3,4-c]pyrrole-l ,3(2H,3aH)-dione.
Ή-NMR (400 MHz, DMSO- 0 δ 12.59 (s, I H), 8.25 (d, J = 7.6 Hz, I H), 7.80- 7.89(m, 3H), 7.41 - 7.43 (in, I H), 7.13 - 7.40 (m, 7H), 4.55 (s, 2H ), 4.26 (s, 2H), 4.15-4.17 (brd, I H), 3.50-3.62 (m, 4H), 3.37-3.40 (brd, I H).
Example 3
4-(4-fluoro-3-( l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin- 1 (2H)-one.
Ή-NMR (400 MHz, DMSO-dfe) δ 12.74 (s, I H), 12.58 (s, I H), 8.25 (d, J = 7.6 Hz, I H), 7.97 (dd, J = 8 & 3.6 Hz, I H), 7.80 - 7.90 (m, 2H), 7.42-7.59 (m, 3H), 7.25 (t, J = 9 Hz, 1 H), 4.56 (s, 2H ), 4.35 (s, 2H ), 4.25-4.29 (brd, 2H ).
Example 4
4-(3-(5-(cyclopropanecarbonyl) octahydropyrrolo [3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin- 1 (2H)-one.
Ή-NMR (400 MHz, D SO-<¾) 5 12.59 (s, I H), 8.24 (d, J = 1.2 Hz, I H), 7.96 (dd, J = 8 & 4.8 Hz, I H), 7.82 - 7.90 (m, 2H), 7.40 (dd, J= 6.8 & 5.2 Hz, 2H), 7.23 (dd, J= 9.6 & 3.6 Hz, 2H), 4.32 (s, 2H ), 3.89-3.90 (brt, 1 H), 3.70-3.80 (m, 1 H), 3.50-3.60 (m, I H), 3.40-3.49 (m, 2H), 3.22-3.26 (m, 2H), 3.1 1 - 3.1 6 (m, 2H), 2.90-3.0 (m, I H), 1.17- 1 .25 (m, 1 H), 0.69-0.72 (brt, 4H).
Example 5
4-(3-(l -(cyclopropylmethyl)-l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4- fluorobenzyl)phthalazin- 1 (2H)-one
I H NMR (400 MHz, DMSO-d6): δ 12.77 (brs, I H), 8.30 (d, J= 7.6 Hz, I H), 8.03 (dd, J= 7.6 & 4.8 Hz, I H), 7.83-7.91 (m, 2H), 7.46-7.58 (m, 3H), 7.24-7.29 (brt, I H), 4.57 (s, 2H), 4.37 (s, 2H), 4.25-4.29 (brd, 2H), 4.0 (d, J= 7.2 Hz, 2H), 1 .12-1.19 (m, I H), 0.35-0.47 (m, 4H).
Example 6
4-(3-(5-(cyclopropylmethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyI)-4- fliiorobenzy phthalazin- 1 (2H)-one
1 H NMR (400 MHz, CDC13): δ 1 0.30 (s, 1 H), 8.44-8.47 (m, 1 H), 7.70-7.79 (m, 3H), 7.35 (dd, J= 6.4 & 2.4 Hz, 1 H), 7.26-7.31 (m, 1 H), 7.0-7.05 (brt, 1 H), 4.27 (s, 2H ), 3.75-3.76 (brd, 2H), 3.45-3.47 (m, 1 H), 2.88-3.24 (m, 4H), 2.36-2.52 (m, 5H), 0.98 (brs, I H), 0.56-0.58 (brd, 2H), 0.19-0.58 (brd, 2H).
Example 7
4-(4-fluoro-3-(5-(2,2,2-trifluoroethyI)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl)phthalazin- 1 (2H)-one
IH NMR (400 MHz, In CDC13): δ 10.28 (s, IH), 8.45-8.47 (m, IH), 7.70-7.77 (m, 3H), 7.36 (dd, J=6.4 & 2.4, IH), 7.26-7.29 (m, IH), 6.99-7.Ό4 (m, IH), 4.27 (s, 2H ), 3.86-3.91 (m, IH), 3.61-3.65 (m, IH), 3.48-3.53 (m, IH), 3.15-3.19 (m, IH), 3.0-3.07 (m, 1 H), 2.86-2.99 (m, 1 H), 2.69-2.82 (m, 3H), 2.50-2.53 (m, IH)
Example 8
4-(3-(5-(cyclopropylmethyl)-l, 2,3,4,5, 6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)- 4-fluorobenzyl)phthalazin- 1 (2H)-one
IH NMR (400 MHz, DMSO-d6): δ 12.59 (s, IH), 8.27 - 8.25 (m, IH), 7.97 (d, J = 7.6 Hz, IH), 7.91 - 7.87 (m, IH), 7.83 (dd, J = 7.6 Hz & 1.2 Hz, IH), 7.42 (dd, J = 10.4 Hz & 5.2 Hz, 2H), 7.26 - 7.22 (m, 1 H), 4.32 (s, 2H ), 4.23 (s, 2H), 3.92 (s, 2H), 3.78-3.46 (m, 3H), 3.42 (s, IH), 2.69 - 2.66 (m, IH), 1.0-0.7 (m, IH), 0.5-0.035 (m, 2H), 0.2 (m, 2H).
Example 9
4-(3-(5-benzyloctahydropyrroIo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin- l(2H)-one hydrochloride
IH NMR (400 MHz, DMSO-d6): δ 12.62 (s, IH), 10.81 (s, IH), 8.26 (m, IH), 8.32
- 7.98 (m, IH), 7.87 - 7.61 (m, IH), 7.59 (dd, IH), 7.53 (dd, IH), 7.44 (m, 4H), 7.38
- 7.35 (m, 1 H ), 7.27 - 7.19 (m, 1 H), 4.39 - 4.31 (m, 4H), 3.72 (d, 1 H), 3.28 (m, 1 H), 3.16 (m, 2H), 2.99 - 2.89 (m, 2H), 2.73 - 2.49 (m, 2H).
ExamplelO
4-(4-fluoro-3-(5-(2-((3-fluorophenyl)thio)-2-methylpropanoyl)octahydropyrrolo[3,4- c]pyrrole-2-carbonyl)benzyI)phthalazin-l(2H)-one
1H NMR (400 MHz, DMSO-d6): δ 12.58 (s, IH), 8.25 (d, J = 6.4 Hz, IH), 7.90 (d, IH), 7.88 (t, IH), 7.82 (t, IH), 7.37 (d, J = 6.4 Hz, IH), 7.34 (m, 2H), 7.19 (t, 2H), 7.1 (m, 2H), 4.45 (d, 2H), 4.39 (t, 4H ), 4.30 (s, 2H), 3.43 - 3.36 (m, 3H), 3.17 (d, 2H), 1.4 (s, 6H).
Example 11
2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l-yl)methyl)benzoyl) tetrahydropyrrolo[3,4-c]pyrrole-l,3(2H,3aH)-dione
Ή NMR (400 MHz, DMSO-d6): δ 12.59 (s, IH), 8.25 (dd, J = 7.6 Hz & 0.6 Hz, IH), 7.94 (d, J = 7.6 Hz, IH), 7.86 - 7.80 (m, 2H), 7.35 (m, 1 H), 7.32 (dd, IH), 5.29 - 7.24 (m, 4H), 7.23 - 7.20 (m, 2H), 4.32 (s, 2H ), 3.63 (m, IH), 3.47 (m, IH), 3.46 (m, 2H), 3.36 (m, lH),2.9(dd, IH), 2.60-2.8 (m, 3H), 2.51 -2.49 (m, 2H), 2.1 (m, IH) Example 12
4-(3-(l-(cyclopropanecarbonyl)-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoIe-5-carbonyl) -4-fluorobenzyl)phthalazin- 1 (2H)-one
IH NMR (400 MHz, DMSO-d6): δ 12.57-12.60 (brd, IH), 8.26 (d, J= 7.6 Hz, IH), 7.97 (d, J= 7.6 Hz, IH), 7.69-7.92 (m, 3H), 7.45-7.49 (m, 2H), 7.25-7.30(brt, H), 4.80(brs, 2H), 4.37 (brs, 2H), 4.34 (s, 2H), 4.28(brs,lH), 2.97-3.0 (m, IH), 1.07-1.23 (m, 4H). Example 13
tert-butyl 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l -yl)methyl)benzoyl) hexahydropyrrolo[3,4-c]pyrrole-2( 1 H)-carboxylate
I H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1 H), 8.25 (t, J = 8 Hz, 1 H), 7.97 (d, J = 8 Hz, 1 H), 7.82 - 7.88 (m, 2H), 7.39 - 7.41 (m, 2H), 7.21 - 7.23 (brt, 1 H), 4.32 (s, 2H ), 3.68 (brs, I H), 3.50 (brd, 2H), 3.39-3.41 (brd, 2H), 3.00-3.03 (brt, 2H), 2.81 -2.89 (brd, 2H), 1.39 (s, 9H).
Example 14
4-(4-fluoro-3-(hexahydro- l H-furo[3,4-c]pyrroIe-5-carbonyl)benzyl)phthalazin- l (2H)- one
1 H NMR (400 MHz, DMSO-d6): δ 12.59 (s, I H), 8.26 (dd, J= 7.6 & 0.8 Hz, I H), 7.97 (d, J= 8 Hz, I H), 7.80-7.89 (m, 2H), 7.39-7.43 (m, 1 H), 8.35 (dd, J= 6.4& 2 Hz, I H), 7.19-7.23 (brt, I H), 4.32 (s, 2H), 3.74-3.78 (m, IH), 3.64-3.69 (m, 2H), 3.33- 3.55 (m, 4H), 3.01 -3.02 (m, 2H), 2.91 -3.07 (m, 2H).
Example 15
4-(4-fluoro-3-(octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin- l (2H)- one
lHNMR (400 MHz, DMSO-d6): δ 12.60 (s, IH), 8.26 (dd, J = 7.6& 0.8 Hz, IH), 7.96 (d, J = 7.6 Hz, IH), 7.82 - 7.88 (m, 2H), 7.32 - 7.34 (m, IH), 7.18 - 7.23 (m, IH), 4.32 (s, 2H ), 3.67-3.72 (m, IH), 3.30-3.40 (m, 2H),2.77-2.96 (m, 2H), 2.58- 2.73 (m, 4H), 2.41-2.44 (m, IH).
Example 16
4-(4-fluoro-3-(5-(methylsulfonyI)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-l(2H)-one
IH NMR (400 MHz, DMSO-d6): δ 12.58 (s, IH), 8.26 (dd, J = 8 & 1.2 Hz, IH), 7.96 (d, J = 8 Hz, IH), 7.82-7.89 (m, 2H), 7.39-7.41 (brd, 2H), 7.19-7.24 (m,lH), 4.32 (s, 2H ), 3.69-3.74 (m, IH), 3.39-3.50 (m, 5H), 2.98-3.15 (m, 4H), 2.91 (s, 3H).
Example 17
4-(4-fluoro-3-( 1 -(methylsulfonyl)- 1 ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl)phthalazin- -one
IH NMR (400 MHz, DMSO-d6): δ 12.59 (brd, IH), 8.26 (d, J= 7.6 Hz, IH), 7.97 (d, J= 8 Hz, IH), 7.72-7.90 (m, 3H), 7.47-7.50 (m, 2H), 7.29-7.30(m, IH), 4.81 (brs, IH), 4.58 (brs, 2H), 4.34 (brs, IH), 3.52-3.57(brd, 3H).
Example 18
4-(3 -(5 -benzoy loctahydropyrro lo[3 ,4-c] pyrro le-2-carbony l)-4-fluorobenzy 1) phthalazin-l(2H)-one
IH NMR (400 MHz, DMSO-d6): δ 12.59 (s, IH), 8.25 (d, J = 7.2 Hz, IH), 7.80 - 7.96 (m, 3H), 7.23-7.50 (m, 7H), 7.21-7.23 (m,lH), 4.30- 4.33 (brd, 2H ), 3.38-3.75 (m, 5H).
Example 19
4-(3-(5-(2,4-difluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l -one
IH NMR (400 MHz, CDCI3): δ 12.59 (s, IH), 8.44-8.46 (m, IH), 7.69-7.78 (m, 3H), 7.31-7.37 (m, 2H), 7.26-7.29 (m, IH), 6.99-7.04 (brt, IH), 6.75-6.86 (m, 2H), 4.27 (s, 2H), 3.83-3.88 (m, IH), 3.60-3.66 (m, 4H), 3.14-3.18 (m, IH), 2.51-2.88 (m, 5H), 2.33-2.35 (m, IH).
Example 20
4-(3-(5,6-dihydro-4H-furo[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl)phthalazin- l(2H)-one
1 H NMR (400 MHz, DMSO-d6): δ 12.59 (s, 1 H), 8.26 (dd, J = 7.6 Hz & 1.2 Hz, IH), 7.97 (d, J = 7.6 Hz, IH), 7.91 - 7.87 (m, IH), 7.85 - 7.81 (m, IH), 7.53 (d, J = 1.2 Hz, IH), 7.46- 7.42 (m, 2H), 7.41- 7.40 (d, J= 1.2 Hz, IH ), 7.28 - 7.23 (m, IH), 4.56 (s, 2H), 4.34 (s, 2H), 4.26 (s, 2H). Example 21
4-(4-fluoro-3-(5-methyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin- l(2H)-one
IH NMR (400 MHz, CDC13): 59.90 (s, IH), 8.44-8.47 (m, IH), 7.70-7.79 (m, 3H), 7.27-7.52 (m, 2H), 6.99-7.04 (brq, IH), 4.26 (s, 2H ), 3.85-3.90 (m, IH), 3.62-3.64 (m, IH), 3.44-3.51 (m, IH), 3.19-3.21 (m, IH), 2.73-2.97 (m, 4H).
Example 22
5-(2-fIuoro-5-((4-oxo-3,4-dihydrophthaIazin-l- yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-l,3(2H,3aH)-dione
IH NMR (400 MHz, DMSO-d6): δ 12.58 (s, IH), 11.4 (s, IH), 8.26 (dd, J = 7.6 Hz & 0.8 Hz, IH), 7.87-7.96 (m, 2H), 7.80-7.85 (m, IH), 7.41-7.43 (m, IH), 7.37 (dd, J = 6.4 Hz & 2.4 Hz, IH), 7.20- 7.24 (brt, IH), 4.31 (s, 2H ), 4.09-4.12 (brd, IH), 3.38- 3.58 (m,5H).
Example 23
4-(4-fIuoro-3-(octahydrocyclopenta[c]pyrrole-2-carbonyl)benzyl)phthalazin-l(2H)- one
IH NMR (400 MHz, CDCI3): δ 10.04 (s, IH), 8.44-8.46 (m, IH), 7.70-7.77 (m, 3H), 7.24-7.33 (brt, IH), 7.01-7.03 (m, IH), 6.99-7.03 (brt, IH), 4.26 (s, 2H), 3.79-3.84 (m, IH), 3.43-3.49 (m, 2H), 3.0-3.04 (m, IH), 2.60-2.72 (m, 2H), 1.49-1.88 (m, 6H). Example 24
4-(4-fluoro-3-(5-(4-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-l(2H)-one
1 H NMR (400 MHz, CDCI3): δ 10.18 (s, IH), 8.44-8.46 (m, IH), 7.69-7.76 (m, 3H), 7.33-7.35 (m, IH), 7.25-7.34 (m, 3H), 6.96-7.04 (m, 3H), 4.27 (s, 2H ), 3.83-3.88 (m, IH), 3.45-3.64 (m, 4H), 3.13-3.17 (m, IH), 2.80-2.90 (m, 2H), 2.62-2.63 (m, IH), 2.49-2.52 (m, 2H), 2.28-2.31 (m, IH).
Example 25
4-(4-fluoro-3-(5-(2-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-l(2H)-one
IH NMR (400 MHz, CDC13): δ 10.09 (s, IH), 8.44-8.46 (m, IH), 7.69-7.76 (m, 3H), 7.34-7.37 (m, 2H), 7.21-7.28 (m, 2H), 6.99-7.12 (m, 3H), 4.26 (s, 2H ), 3.84-3.89 (m, IH), 3.59-3.65 (m, 3H), 3.45-3.50 (m, IH), 3.14-3.18 (m, IH), 2.8-2.9 (m, 2H), 2.67- 2.69 (m, IH), 2.53-2.61 (m, 2H), 2.33-2.36 (m, IH).
Example 26
4-(4-fluoro-3-(5-(2-4-(4-fluoro-3-(5-((6-methoxypyridin-2-yl)methyl)
octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-l(2H)-one
I H NMR (400 MHz, CDC13): 5 10.19 (s, I H), 8.43-8.46 (m, I H), 7.69-7.76 (m, 3H), 7.51 -7.55 (m, 1 H), 7.34-7.36 (m, 1 H), 7.26-7.28 (m, 1 H), 7.0-7.04 (brt, 1 H), 6.95 (d, J = 6.8 Hz, 1 H), 6.60 (d, J = 8.4 Hz, I H), 4.26 (s, 2H ), 3.91 (s, 3H), 3.85-3.91 (m, I H), 3.18-3.22 (m, I H), 2.60-2.79 (m, 5H), 2.08-2.44 (m, I H).
Example 27
5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl)benzoyl)-2-methyl tetrahydropyrrolo[3,4-c]pyrrole-l ,3(2H,3aH)-dione
I H NMR (400 MHz, DMSO-d6): δ 10.17 (s, 1 H), 8.45-8.47 (m, I H), 7.74 - 7.82 (m, 2H), 7.69-7.71 (m, 1 H), 7.26-7.34 (m, 2H), 7.02- 7.06 (m, 1 H), 4.45-4.49 (brd, 1 H ), 4.26 (s, 2H), 3.58-3.69 (m, 2H), 3.36-3.46 (m, 2H), 3.0 (s, 3H).
Example 28
Mixture of 4-(4-fluoro-3-( 1 -methyl- 1 ,4,5, 6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl)phthalazin- l(2H)-one compound with 4-(4-fluoro-3-(2-methyl- 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyI)phthalazin- l(2H)-one (1 :3)
I H NMR (400 MHz, DMSO-d6): δ 12.59 (s, I H), 8.24-8.27 (m, I H), 7.96-7.99 (m, I H), 7.81 -7.90 (m, 2H), 7.43-7.56 (m, 3H), 7.23-7.27 (m, I H), 4.54 (s, 2H), 4.33 (s, 2H), 4.23-4.27 (brd, 2H), 3.82 (s, 3H). Example 29
4-(3-(2,2-dioxido-3,4,5,6-tetrahydro-l H-thieno[3,4-c]pyrrole-5-carbonyl)-4- fluorobenzyl)phthalazin-l (2H -one
1 H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1 H), 8.27 (d, J = 7.6 Hz, 1 H), 7.98 (d, J = 8 Hz, I H), 7.91 (dd, J = 14 Hz & 6.8 Hz, 1 H), 7.85 - 7.81 (m, 1H), 7.45 - 7.44 (m, 2H), 7.28 - 7.23 (m, 1 H), 4.35 - 4.32 (d, 4H ), 4.06 (s, 2H), 4.007 (s, 2H), 3.88 (s, 2H).
Example 30
4-(3-(5,6-dihydro-4H-thieno[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl)phthalazin- l (2H)-one
1 H NMR (400 MHz, DMSO-d6): 5 12.58 (s, 1 H), 8.26 (dd, J = 8 Hz & 1 .2 Hz, 1 H), 7.97 (d, J = 7.6 Hz, I H), 7.91 - 7.87 (m, I H), 7.85 - 7.81 (m, I H), 7.46 - 7.43 (m, 2H), 7.29 - 7.23 (m, 2H), 7.16 (m, 1 H ), 4.59 (s, 2H), 4.34 (s, 2H), 4.29 (s, 2H). Example 31
4-(4-fluoro-3-( l ,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin- 1 (2H)-one
I H NMR (400 MHz, DMSO-d6): δ 12.59 (s, I H), 8.26 (m, J = 7.6Hz & 1.2 Hz, I H), 7.96 (d, J = 7.6 Hz, 1 H), 7.90 - 7.84 (m, 1 H), 7.82 - 7.80 (m, 1 H), 7.44 - 7.40 (m, 2H), 7.22 - 7.21 (m, I H), 4.32 (s, 2H ), 4.26 - 4.19 (d, 2H), 3.96 - 3.87 (d, 2H), 3.63 - 3.59 (d, 2H), 3.58 - 3.48 (d, 2H).
Example 32
4-(4-fluoro-3-(5-phenyloctahydropyrrolo[3,4-c]pyrroIe-2-carbonyl)benzyl)phthalazin- l(2H)-one
I H NMR (400 MHz, DMSO-d6): δ 12.58 (s, I H), 8.25 (dd, J=7.6 & 1 .2 Hz, I H), 7.95 (d, J=7.6 Hz, I H), 7.80-7.85 (m, 2H), 7.36-7.42 (m, 2H), 7.14-7.23 (m, 3H), 6.62 (t, J=7.6 Hz, I H), 6.52 (d, J=8 Hz, 2H), 4.31 (s, 2H ), 3.74-3.79 (m, I H), 3.42-3.48 (m, 3H), 3.32-3.36 (m, I H), 3.18-3.22 (m, I H), 2.96-3.10 (m, 4H)
Example 33
4-(4-fluoro-3-(5-methyl- l ,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl) phthalazin-l (2H)-one
I H NMR (400 MHz, DMSO-d6): δ 12.59 (s, I H), 8.26 (dd, J = 8 Hz & 0.8 Hz, I H), 7.96 (d, J = 7.6 Hz, I H), 7.90 - 7.86 (m, I H), 7.84 - 7.80 (m, I H), 7.43 - 7.40 (m, 2H), 7.25 - 7.21 (m, IH), 4.32 (s, 2H ), 4.19 (s, 2H), 3.58 (s, 2H), 3.43 (s, 2H), 2.42 (s, 3H).
Example 34
4-(3-((3ai?,8bi?)-decahydropyrrolo[3,4-a]pyrrolizine-2-carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one
I H NMR (400 MHz, DMSO-d6): 5 10.5 - 10.2 (d, I H), 8.44 - 8.46 (m, I H), 7.71 - 7.77 (m, 3H), 7.41 - 7.38 (m, I H), 7.24 (d, J = 2.4 Hz, I H), 7.02 - 6.99 (m, I H), 4.24 (s, 2H), 3.89 - 0.88 (m, 15H ).
Example 35
4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin- 1 (2H)-one
I H NMR (400 MHz, CDCI3): δ 10.02 (s, I H), 8.44-8.46 (m, I H), 7.69-7.79 (m, 3H), 7.29-7.40 (m, 2H), 7.04-7.17 (m, 2H), 4.73-4.77 (brd, 2H), 4.37-4.39 (brd, 2H), 4.28 (s, 2H), 3.89-3.90 (brd, 2H).
Example 36
4-(4-fluoro-3-( l -methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin- 1 (2H)-one
1 H NMR (400 MHz, CDC13): δ 9.98 (s, 1 H), 8.44-8.47 (m, 1 H), 7.70-7.80 (m, 3H), 7.31-7.40 (m, 2H), 7.06-7.30 (m, 2H), 4.72-4.78 (brd, 2H), 4.37-4.44 (brd, 2H), 4.28- 4.29 (brd, 2H), 3.73-3.85 (brd, 3H).
Example 37
2-((5-(2-fluoro-5-((4-oxo-3,4-dihydrophthaIazin- l -yl)methyl)benzoyl)
hexahydropyrrolo[3,4-c]pyrro]-2( l H)-yl)methyl)-6-methoxypyridine-l -oxide
IH NMR (400 MHz, DMSO-d6): δ 12.70 (s, IH), 8.26 (d, J = 8.8 Hz, IH), 8.83-8.91 (m, 3H), 7.67-7.70 (m, IH), 7.41-7.45 (m, IH), 7.28-7.30 (m, IH), 7.16-7.23 (m, IH), 6.82 (d, J = 8 Hz, IH), 4.40-4.41 (brd, 2H ), 4.31 (s, 2H), 3.82 (s, 3H), 3.70-3.73 (brd, IH), 3.37-3.47 (m,3H), 3.12-3.25 (m,3H), 2.99-3.02 (brd, IH).
Example 38
4-(3-(5-(difluoromethy])octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one
IH NMR (400 MHz, CDC13): δ 10.25 (s, 1 H), 8.45-8.47 (m, IH), 8.21-8.24 (m, IH), 7.71-7.79 (m, 3H), 7.30-7.32 (m, IH), 7.26-7.29 (m, IH), 7.01-7.05 (m, IH), 4.27 (s, 2H ), 3.87-3.93 (m, IH), 3.73-3.82 (m, IH), 3.56-3.70 (m, IH), 3.46-3.50 (m, IH), 3.30-3.34 (m, IH), 3.18-3.23 (m, IH), 2.92-2.95 (m, IH).
Example 39
4-(4-fluoro-3-((3aR,6aS)-5-oxoocta ydrocyclopenta[c]pyrrole-2-carbonyl)benzyl) phthalazin- 1 (2H)-one
IH NMR (400 MHz, CDC13): δ 10.63 (s, IH), 8.47-8.49 (m, IH), 7.72-7,81 (m, 3H), 7.37-7.39 (m, IH), 7.30-7.33 (m, IH), 7.02-7.04 (brt, IH), 4.30 (s, 2H), 3.95-4.00 (m, I H), 3.55-3.65 (m, 2H), 3.1 8-3.22 (m, I H), 2.94-3.10 (m, 2H), 2.44-2.61 (m, 2H), 2.22-2.28 (m, I H), 2.08-2.18 (m, I H).
Example 40
Mixture of 1 & 2 Ethyl 4-(3-(2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4- fluorobenzyl)phthaIazin-l (2H)-one
I H NMR (400 MHz, DMSO-d6): δ 12.60 (s, I H), 8.25 (t, I H), 7.99 (dd, J = 7.6 Hz & 4 Hz, I H), 7.91 - 7.87 (m, I H), 7.85 - 7.81 (m, 1 H), 7.61 - 7.42 (m, 3H), 7.28 - 7.23 (m, 1 H), 5.3 1 (s, 1 H ), 4.55 (d, 1 H), 4.52 - 4.43 (d, 2H), 4.34 (s, 2H), 4.28 - 4.20 (t, 2H), 4.14 - 4.08 (m, 2H), 3.39 - 3.35 (m, 2H), 1.67 - 1.10 (m, 6H).
Example 41
4-(3-(2-ethyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one
1 H NMR (400 MHz, DMSO-d6): 5 12.59 (s, 1 H), 8.26 (d, J = 8 Hz, 1 H), 7.98 (d, J = 7.6 Hz, I H), 7.88 (d, J = 8 Hz, 1 H), 7.84 (d, J = 7.6 Hz, 1 H), 7.61 (s, 1 H), 7.46 (d, J = 5.6 Hz, 2H), 5.25 (m, I H ), 4.55 (s, 2H), 4.33 (s, 2H), 4.26 (d, 2H), 4.10 (q, 2H), 1.36 - 1.32 (m, 3H).
Example 42
4-(3-(l-ethyl-l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl) phthalazin- 1 (2H)-one
IH NMR (400 MHz, DMSO-d6): δ 10.37 - 10.34 (d, 2H), 8.47 - 8.45 (dd, 1 H), 7.82 - 7.22 (m, 3H), 7.41 - 7.33 (m, 2H), 7.20 (s, I H), 7.13 - 6.99 (m, I H), 4.82 (s, I H), 4.72 (s, I H ), 4.46 (s, IH), 4.37 (s, I H), 4.37 - 4.31 (d, 2H), 4.15 (q, 2H), 1 .48 (t,2 H), 1.37 (t, I H).
Example 43
4-(4-fluoro-3-(l-isopropyl-l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoIe-5-carbonyl) benzyl)phthalazin- 1 (2H)-one
I H NMR (400 MHz, DMSO-d6): δ 12.56 (s, I H), 8.24 (d, J = 7.6 Hz, 1 H), 7.95 (t, 1 H), 7.87 (t, 1 H), 7.81 (t, 1 H), 7.46 - 7.42 (m, 2H), 7.27 - 7.22 (m, 1 H), 7.15 (s, 1 H), 4.74 (s, 1 H), 4.48 (s, 1 H ), 4.45 (m, 1 H), 4.32 (s, 2H), 4.30 - 4.26 (m, 1 H), 4.1 (s, I H), 1 .37 (d, 3H), 1.23 (t, 3H).
Example 44
Mixture of (1 & 2 isopropyl ) 4-(4-fluoro-3-(l ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole- 5-carbony l)benzy l)phthalazin- 1 (2H)-one
IH NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1 H), 8.26 (d, J = 7.6 Hz, 1 H), 7.98 (d, J = 8 Hz, 1 H), 7.91 - 7.81 (m, 2H), 7.48 - 7.42 (m, 2H), 7.29 - 7.23 (m, IH), 7.17 (s, IH), 4.55 (s, IH), 4.49 -4.44 (m, IH), 4.33 (s, 2H), 4.29 (s, lH),4.24(s, IH), 1.40 (dd,5H), 1.25 (t, IH).
Example 45
4-(4-fluoro-3-(2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5- carbonyl)benzyl) phthalazin-l(2H)-one
1 H NMR (400 MHz, DMSO-d6): δ 12.57 (s, 1 H), 8.26 (d, J = 7.6 Hz & 1.2 Hz, 1 H), 7.98 (t, IH), 7.91 -7.87 (m, IH), 7.85-7.81 (m, IH), 7.64-7.50 (d, IH), 7.46- 7.42 (m, 2H), 7.27 (t, IH), 4.55 (s, 2H), 4.49 - 4.46 (m, 1 H ), 4.33 (s, 2H), 4.29 (s, 1 H), 4.24 (s, 1 H), 1.40 - 1.38 (dd, 6H).
Example 46
4-(3-((3aR,6a5)-5,5-difluorooctahydrocyclopenta[c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l (2H)-one
1 H NMR (400 MHz, CDCI3): δ 10.07 (s, IH), 8.45-8.47 (m, IH), 7.70-7.79 (m, 3H), 7.35-7.37 (m, IH), 7.24-7.31 (m, IH), 7.01-7.05 (brt, IH), 4.27 (s, 2H), 3.82-3.87 (m, IH), 3.65-3.70 (m, IH), 3.51-3.56 (m, IH), 3.18-3.22 (m, IH), 2.80-2.94 (m, 2H), 2.26-2.45 (m, 2H), 1.87-2.08 (m, 2H).
Example 47
4-(4-fluoro-3-(5-(2-methoxyethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbony])benzyI) phthalazin- 1 (2H)-one
IH NMR (400 MHz, CDCI3): δ 10.25 (s, IH), 8.44-8.47 (m, IH), 7.71-7.79 (m, 3H), 7.34-7.36 (m, IH), 7.26-7.30 (m, IH), 6.99-7.04 (brt, IH), 4.27 (s, 2H ), 3.64-3.79 (m, 2H), 3.50-3.53 (m, 2H), 3.42-3.47 (m, IH), 3.36 (s, 3H), 3.16-3.18 (brd, IH), 2.80- 2.97 (m, 2H), 2.64-2.68 (m, 2H), 2.41-2.42 (brd, IH).
Example 48
N-((3ai?,6atS)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l-yl)methyl)benzoyl) octahydrocyclopenta[c]pyr de
IH NMR (400 MHz, CDC 13): δ 10.38 (s, IH), 8.44-8.46 (m, IH), 7.72-7.78 (m, 3H), 7.42-7.44 (m, IH), 7.26-7.29 (m, IH), 6.98-7.03 (brt, IH), 5.57 (brd, IH), 4.40-4.42 (m, IH), 4.27 (s, 2H), 3.79-3.85 (m, IH), 3.48-3.60 (m, 2H), 3.06-3.10 (m, IH), 2.78- 2.85 (m, 2H), 1.90-2.00 (m, IH), 1.70-1.88 (m, IH), 1.00-1.03 (m, 2H), 0.83-0.90 (m, IH), 0.73-0.75 (m, 2H)
Example 50
4-(4-fluoro-3-(l-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-l(2H)-one hydrobromide
IH NMR (400 MHz, DMSO-d6): δ 12.59 (d, J = 3.6 Hz, IH), 8.26(d, J = 7.6 Hz, 1 H), 8.005 - 7.92 (m, 1 H), 7.911 - 7.87 (m, 1 H), 7.85 - 7.81 (m, 1 H), 7.48 - 7.43 (m, 2H), 7.30 - 7.25 (m, IH), 7.15 (brs, IH), 4.69 (s, IH), 4.53 (s, IH ), 4.42 (s, IH), 4.34 (s, 2H), 4.21 (s, IH), 3.78 - 3.66 (brd, 3H).
Example 51
4-(4-fluoro-3-(l-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin- 1 (2H)-one hydrochloride
lHNMR (400 MHz, DMSO-d6): δ 12.59-12.59 (d, J = 3.6Hz, IH), 8.26 (d, J = 7.6Hz, IH), 7.98 (t, J = 8Hz, IH), 7.89 (t, J = 3.4Hz, IH), 7.83 (t, J = 7.4Hz, IH), 7.43-7.48 (m, 2H), 7.26-7.28 (m, IH), 7.15-7.27 (brd, IH), 4.53-4.69 (brd, 2H), 4.34 (s, 2H), 4.21-4.42 (brd, 2H), 3.66-3.78 (brd, 3H).
Example 52
4-(4-fluoro-3-(l -methyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin- l(2H)-one sulfate
lH MR(400MHzDMSO-d6):512.59-12.58 (d, J = 3.2Hz, IH), 8.26 (d, J = 8Hz, IH), 7.97 (m, IH), 7.89 (m, IH), 7.84 (m, IH), 7.48-7.43 (m, 2H), 7.15 (s, H), 4.53 (s, 1H),4.41 (s, 1H),4.34 (s, 2H),4.21 (s, IH), 3.78 (s, 3H), 3.73 (m, IH).
Example 53
4-(4-fluoro-3-(l -methyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1 (2H)-one 4-methylbenzenesulfonate
IH NMR (400 MHz, DMSO-d6): δ 12.59-12.58 (d, J = 3.2Hz, IH), 8.26 (d, J = 7.6Hz, IH), 7.98 (m, IH), 7.904 (m, IH), 7.87-7.81 (m, IH), 7.48-7.43 (m, 4H), 7.3- 7.28 (m, IH), 7.11 (m, 2H), 4.69 (s, I H), 4.53 (s, 1 H), 4.4t (s, IH), 4.21 (s, IH), 3.72 (s, 3H), 2.28 (s, 3H)
Example 54
4-(4-fluoro-3-(l-methyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-l(2H)-orte benzenesulfonate
IH NMR (400 MHz, DMSO-d6): δ 12.59-12.59 (d, J = 3.2Hz, IH), 8.26 (d, J = 8Hz, IH), 7.87-7.92 (m, IH), 7.83 (t, J = 7.6Hz, IH), 7.58-7.61 (m, 2H), 7.43-7.48 (m, 2H), 7.15-7.34 (m, 7H), 4.53-4.69 (brd, 2H), 4.34 (s, 2H), 4.21-4.41 (brd, 2H), 3.66-3.78 (brd, 3H).
Example 55
5-(2-fluoro-5-((4-oxo-3,4-dihydrophthaIazin-l-yl)methyl)benzoyl)-2-isopropyl- 2,4,5, 6-tetrahydropyrrolo[3,4-c]pyrazol-2-iLim hydrogensulfate
IH NMR (400 MHz, DMSO-d6): δ 12.58 (s, lH), 8.26 (dd, J = 8 Hz & 1.2 Hz, IH), 7.98 (dd, J = 7.6 Hz & 2.4 Hz, 1 H), 7.91 - 7.87 (m, 1 H), 7.85 - 7.81 (m, 1 H), 7.64 - 7.51 (brd, 1 H), 7.47 - 7.42 (m, 2H), 7.28 - 7.23 (m, 1 H), 4.55 (s, 2H), 4.51 - 4.45 (m, 1 H ), 4.33 (s, 2H), 4.29 - 4.24 (brd, 2H), 1.40 - 1.38 (brd, 4H).
Example 56
4-(3-(l-cyclopropyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazole-5-carbonyI)-4- fluorobenzyl)phthalazin-l(2H)-one
Ή NMR (400 MHz, DMSO-i¾): S 12.58 (d, J = 2.4 Hz, lH), 8.24(d, J = 7.6 Hz, lH), 7.98 -
7.37 (m, 1H), 7.89-7.85 (m, !H),7.81 (t, 1H), 7.47 - 7.39 (m, 2H), 7.28 - 7.22 (m, 1H), 7.14
(d, iH), 4.70 (s, 1H), 4.48 (s, 1H ), 4.42 (s, 1H), 4.32 (s, 2H), 4.16 (s, 1H), 3.57 - 3.44 (m, 1 H), 0.98- 0.82 (m, 4H).
The following compounds can be synthesized following the same procedure as described for example 1 and are considered to be encompassed within the scope of the present invention.
4-(4-fluoro-3-( 1 -propyl- 1 ,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-l(2H)-one
2-(cyclopropanecarbonyl)-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l-yl)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-l,3(2H,3aH)-dione
5-(cyclopropanecarbonyl)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l-yl)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-l,3(2H,3aH)-dione
4-(4-fluoro-3-(2-(trifluoromethyl)-5,6-dihydro-4H-pyrro!o[3,4-d]oxazoIe-5-carbonyl) benzyl)phthalazin- 1 (2H)-one
4-(3-(2-(cyclopropanecarbonyl)-5,6-dihydro-4H-pyrrolo[3,4-d]oxazole-5-carbonyl)-4- fluprobenzyl)phthalazin-l (2H)-one
4-(4-fIuoro-3-(2-(trifluoromethyl)-4,5,6,6a-tetrahydro-3aH-pyrroio[3,4-d]thiazole-5- carbonyl)benzyl)phthalazin- 1 (2H)-one
5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl)benzoyl)dihydro- l H- furo[3,4-c]pyrrole-4,6(5H,6aH)-dione
5-(cyclopropanecarbonyl)-2-(2-fIuoro-5-((4-oxo-3,4-dihydrophthalazin-l -yl)methyl) benzoyl)pyrrolo[3,4-c]pyrrol - 1 ,3(2H,5H)-dione
4-(3-(5-benzyl-l,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4- fluorobenzyl)phthalazin-l (2 -one
5-(cyclopropylmethyl)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin- l - yl)methyl)benzoyl)pyrrolo[ -c]pyrrole-l ,3(2H,5H)-dione
4-(3-(5-(cyclopropanecarbonyl)-l ,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2- carbonyl)-4-fluorobenzyl)phthalazin-l (2H)-one
2-(cyclopropylmethyl)-5-(2-fIuoro-5-((4-oxo-3,4-dihydrophthalazin- l -yl)methyl) benzoyl)tetrahydropyrrolo[3, -c]pyrrole- 1 ,3(2H,3aH)-dione
Biological activity- In vitro study
In vitro study
Potentiation of cell killing activity of Methyl Methane Sulphonate (MMS) by selected compounds according to present invention was evaluated in MCF-7 cell line obtained from National Centre for Cell Science, Pune, by using MTT assay according to general protocol described in Methods in Molecular Biology, Volume-43, In vitro Toxicity Testing Protocol, Chapter-6, page: 137-149. Compounds were tested for PARP 1 activity based on percent cell survival of MCF-7 cells with alkylating agent MMS.
The compounds were tested for PARP- 1 inhibitory activity by using HT universal colorimetric PARP assay kit obtained from Trevigen, following manufacturer's protocol.
The results of the compounds are provided in Table 1 .
Result of Table 1 shows that the compounds are found to possess PARP 1 inhibitory activity, thus have potential to be developed as compounds for therapeutic use.
In vivo study
On basis of the in vitro data, the ability of selected compounds to potentiate the antitumor activity of the methylating chemotherapeutic agent, temozolomide, was evaluated in an SW 620 tumor model.
Animals bearing SW 620 xenograft tumors were treated with the compounds in combination with TMZ (50 mg/ g, po) once daily for 5 consecutive days, after which the tumors were left to grow out. A considerable inhibition of tumor volumes as compared with that of the TMZ alone group was observed for the TMZ plus compounds combinations (mean values given as relative tumor volumes (RTV) [table 2]. The compounds did not exacerbate the systemic toxicity of TMZ, with a maximum mean body weight loss of 9- 10% on day 6 with full recovery of body weight within 3 days and with no mortalities, which indicates that the combination therapy was well tolerated by compounds under the dosing regimen.
Female athymic nude mice were used for antitumor in vivo studies. SW620 colorectal tumor cells (1 x 107 cells per animal) were implanted s.c. into one flank of each mouse. When tumors were palpable ( 10-12 days after implantation), animals were treated (n= 6-8/group) with five daily doses of temozolomide administered per os as a suspension in 0.5% methyl cellulose at 50 mg/kg either alone or in combination with a five daily per os administrations of PARP inhibitor at different doses. Tumor growths were measured using two-dimensional caliper measurements. Tumor volume was calculated using the equation a2 x b / 2, where a is the smallest measurement and b is the largest. Data are presented as median relative tumor volumes (RTV), defined as the calculated tumor volume divided by the calculated tumor volume on the initial day of treatment (day 0). Thus, on day 0, the RTV value is 1 and RTV4 is when the tumor is four times as large as its initial value. Control animals were treated with vehicle ( 15 tween 80 in methyl cellulose) alone tumor growth delay (TGD) = Time to RTV4 in treated group - time to RTV4 control.
Table 1: ln-Vitro PARP-1 activity
PARP 1 IC50 are estimation as calculated from a 4 point dose response curve
Table 2: In vivo antitumor efficacy of compounds in combination with temozolomide (T Z) in an SW620 tumor model b.
Mice were orally dosed once daily for 5 consecutive days. The compounds were administered 45 min before TMZ.

Claims

We Claim:
1. Compound having the structure of general formula (I)
(I) wherein 'A' and 'B' is independently selected from hydrogen, alkyl or connected together to the carbon atoms to form a cycloalkyl, heterocyclyl, aryl or heteroaryl groups, R1 at each occurrence is independently selected from H, halogen, or the groups selected from (Ci-C]2)alkyl, haloalkyl, cycloalkyl, alkylthio or the group (OS02) alkyl, wherein each of these groups are further optionally substituted with suitable substituents;
m = 1-4; L= -O, -S, -NH;
R2 is selected from substituent groups consisting of hydrogen atom, hydroxyl, alkyl, cycloalkyl, oxo, C(0)OR5, -C(0)R5, or -C(0)NR6R7, wherein said alkyl and cycloalkyl groups are further substituted by one or more substituents selected from halogen, hydroxyl, alkyl or alkoxy groups;
R3 and R4 are each independently selected from hydrogen atom, alkyl, hydroxyl, alkoxy, cycloalkyl, - C(0)OR5, -OC(0)R5, -0(CH2)pC(0)OR5, -C(0)R5, - NHC(0)R5, -NR6R7, -OC(0)NR6R7 or -C(0)NR6R7 or alternatively, R3 and R4 together forms an oxo group;
Each of ring atoms ' D' and 'E' is independently selected from C or N atoms; 'D' and Έ' are connected to one another to form 5 membered ring 'X', wherein 'X' is selected from cycloalkyl, heterocyclyl, heteroaryl,' wherein the cycloalkyl, heterocyclyl, heteroaryl is further substituted with one or more suitable substituents;
R5 at each occurrence is independently selected from hydrogen atom, optionally substituted groups selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups; Each of R6 or R7 at each occurrence are independently selected from H, optionally substituted groups selected from hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. Alternatively, R6 and R7 are joined together with nitrogen atom to form a heterocyclyl ring; wherein said heterocyclyl ring contains one or more heteroatoms selected from N, O, S(0)n, n is 0, 1 or 2 and p is 0, 1 or 2.
The compound as claimed in claim 1 , wherein heterocycles representing
is selected from the following bicyclic rings mentioned below
The compound as claimed in claim 1 wherein the substituents on the ring formed by A & B taken together is independently selected from one or more substituent groups selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(0)OR5, -OC(0)R5, -0(CH2)PC(0)OR5, -C(0)R5, - NHC(0)Rs, -NR6R7, -OC(0)NR6R7 or -C(0)NR6R7 wherein each of R5, R6 & R7 are as defined in claim 1 .
The compound as claimed in claim 1 , wherein the substituents on R1 is selected from hydroxyl, oxo, halo, thio, nitro, amino, alkyl, alkoxy, haloalkyl or haloalkoxy groups alone or in combination with other radicals.
5. The compound as claimed in claim 1 wherein the substituents on R5 is selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyi, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents.
6. The compound as claimed in claim 1 wherein the substituents on R6 & R? at each occurrence is independently selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyi, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents.
7. The compound as claimed in claim 1 , wherein the substituents on ring X is selected from halogen, hydroxyl, oxo, optionally substituted groups selected from alkyl, alkoxy, cycloalkyi, heterocyclyl, aryl, heteroaryl, benzyl, OR5, -
C(0)OR5, -OC(0)R5, -0(CH2)pC(0)OR5, C(0)R5, S(0)nR5, -NHC(0)R5, NR6R7, -OC(0)NR6R7 or -C(ONR6R7, wherein each of R5, R6 & R7 are as defined in claim 1 and wherein the alkyl, cycloalkyi, heterocyclyl, aryl, heteroaryl or benzyl group are each independently substituted further with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyi, heterocyclyl, aryl, heteroaryl, oxo,- C(0)OR5, -OC(0)R5, 0(CH2)PC(0)OR5, -C(0)R5, -S(0)nR5„ - NHC(0)R5, NR6R7, -OC(0)NR6R7 or -C(0)NR6R7 groups.
8. The compound as claimed in claim 1 , wherein "aryl" groups is selected from phenyl, naphthyl, tetrahydronaphthyl, indenyl, dihydroindenyl, biphenyl groups. 9. The compound as claimed in claim 1 , wherein the substituents on aryl groups are independently selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyi groups.
10. The compound as claimed in claim 1 , wherein the heteroaryl or heteroaromatic group is selected from pyridyl, thienyl, furyl, pyrrolyl, indolinyl, indolyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, purinyl groups.
1 1. The compound as claimed in claim 1, where in the substitution on heteroaryl or heteroaromatic group is selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups. 12. The compound as claimed in claim 1 , wherein the heterocyclyl group is selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinoyl, thienopyrimidonyi, quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thienopiperidinyl, groups.
13. The compound as claimed in claim 1 , wherein the substitiients on heterocyclyl group is selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups.
14. A compound as claimed in claim 1 selected from the group comprising of:
8. The compound as claimed in any preceding claim preferably selected from the group comprising of:
15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) as claimed in any of the preceding claims and optionally one or more pharmaceutically acceptable carriers, diluents or excipients.
16. A method of treating diseases medicated by the PARP- 1 protein which comprising administering to a patient in need thereof an effective amount of a compound of Formula (I) as claimed in any of the preceding claims or its suitable pharmaceutical composition.
17. A pharmaceutical composition comprising compound of formula (1) along with suitable excipients suitable for the treatment of diseases through the inhibition of poly (ADP-ribose) polymerase- 1 .
18. A medicine for the treatment of diseases medicated by the PARP- 1 protein which comprises administering a therapeutically effective amount of compound of Formula (I) or its pharmaceutical composition as defined in any of the preceding claims to a patient or subject in need thereof.
19. The use of the compound of formula (1) or its pharmaceutical composition as claimed in any of the preceding claims for the manufacture of a medicament for the inhibition of poly (ADP-ribose) polymerase- 1.
EP13828996.2A 2012-12-31 2013-12-23 Substituted phthalazin-1(2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 Not-in-force EP2938598B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL13828996T PL2938598T3 (en) 2012-12-31 2013-12-23 Substituted phthalazin-1(2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
HRP20170219TT HRP20170219T1 (en) 2012-12-31 2017-02-09 Substituted phthalazin-1(2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3742MU2012 2012-12-31
PCT/IN2013/000794 WO2014102817A1 (en) 2012-12-31 2013-12-23 Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1

Publications (2)

Publication Number Publication Date
EP2938598A1 true EP2938598A1 (en) 2015-11-04
EP2938598B1 EP2938598B1 (en) 2016-12-21

Family

ID=54198806

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13828996.2A Not-in-force EP2938598B1 (en) 2012-12-31 2013-12-23 Substituted phthalazin-1(2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1

Country Status (29)

Country Link
US (1) US9598418B2 (en)
EP (1) EP2938598B1 (en)
JP (1) JP5930452B2 (en)
KR (1) KR101652654B1 (en)
CN (1) CN104918917A (en)
AP (1) AP2015008439A0 (en)
AR (1) AR094299A1 (en)
AU (1) AU2013368842B2 (en)
BR (1) BR112015012425A2 (en)
CA (1) CA2890309A1 (en)
CL (1) CL2015001655A1 (en)
CO (1) CO7400872A2 (en)
DK (1) DK2938598T3 (en)
EA (1) EA201591239A1 (en)
ES (1) ES2614885T3 (en)
GE (1) GEP201706691B (en)
HR (1) HRP20170219T1 (en)
HU (1) HUE030613T2 (en)
IL (1) IL238714A0 (en)
MA (1) MA38080A1 (en)
MX (1) MX2015006780A (en)
NZ (1) NZ708255A (en)
PH (1) PH12015501199B1 (en)
PL (1) PL2938598T3 (en)
PT (1) PT2938598T (en)
SG (1) SG11201503670YA (en)
TW (1) TWI553005B (en)
WO (1) WO2014102817A1 (en)
ZA (1) ZA201503218B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (en) 2013-03-12 2015-09-16 Hoffmann La Roche DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
CA2937616A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EP3298005B1 (en) 2015-05-21 2024-01-24 The Regents of The University of California Anti-cancer compounds
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
JP6876685B2 (en) * 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bicyclic compounds as ATX inhibitors
AU2016328436B2 (en) * 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
BR112017026682A2 (en) 2015-09-24 2018-08-14 Hoffmann La Roche new bicyclic compounds as dual action inhibitors of atx / ca
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
WO2017071636A1 (en) * 2015-10-30 2017-05-04 四川科伦博泰生物医药股份有限公司 Phthalazine ketone derivative, and preparation method and use thereof
WO2017101796A1 (en) * 2015-12-16 2017-06-22 四川科伦博泰生物医药股份有限公司 Phthalazinone derivative, and preparation method and use thereof
WO2017223516A1 (en) * 2016-06-24 2017-12-28 The Regents Of The University Of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
JP7090099B2 (en) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー A novel bicyclic compound as an ATX inhibitor
RU2019132254A (en) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг HETEROCYCLIC COMPOUNDS SUITABLE AS DUAL ATX / CA INHIBITORS
LT3483164T (en) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
CN109251204A (en) * 2017-07-13 2019-01-22 中国药科大学 PARP inhibitor, its preparation method and medical usage containing phthalazines -1 (2H) -one structure
CN108164468B (en) * 2018-02-09 2021-02-02 上海卫岑医药科技有限公司 PARP inhibitor, pharmaceutical composition, preparation method and application thereof
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
HRP20251148T1 (en) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag PREPARATIONS THAT ACTIVATE PYRUVATE KINASE R (PKR)
WO2021225407A1 (en) * 2020-05-08 2021-11-11 주식회사 티씨노바이오사이언스 Novel phthalazine derivative having ectonucleotide pyrophosphatase/phosphodiesterase inhibitory activity, and use thereof
US20240208912A1 (en) * 2021-03-11 2024-06-27 Mirati Therapeutics, Inc. MTA-Cooperative PRMT5 Inhibitors
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US20240317762A1 (en) * 2021-07-16 2024-09-26 Oregon Health & Science University Phthalazinone-based parp-1 inhibitors
JP2025509404A (en) * 2022-03-15 2025-04-11 ベイジーン スイッツァランド ゲーエムベーハー 4-(aminomethyl)-6-(1-methyl-1H-pyrazol-4-yl)isoquinolin-1(2H)-one derivatives as MTA-cooperative inhibitors of PRMT5
WO2024046420A1 (en) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 Fused bicyclic compound, and preparation method therefor and use thereof in medicine
CN116874496B (en) * 2023-07-10 2025-07-25 东南大学 Tricyclic compound and preparation method, pharmaceutical composition and application thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
HU228960B1 (en) 2000-10-30 2013-07-29 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL1633724T3 (en) 2003-03-12 2011-10-31 Kudos Pharm Ltd Phthalazinone derivatives
ATE501138T1 (en) 2004-01-05 2011-03-15 Astrazeneca Ab THIOPHENE DERIVATIVES AS CHK-1 INHIBITORS
JP2008510783A (en) 2004-08-26 2008-04-10 クドス ファーマシューティカルズ リミテッド 4-heteroarylmethyl-substituted phthalazinone derivatives
US20060079510A1 (en) 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
EP1869052A1 (en) 2005-04-06 2007-12-26 AstraZeneca AB Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
ES2361566T3 (en) 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal USE OF PARP-1 INHIBITORS.
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
UY30639A1 (en) 2006-10-17 2008-05-31 Kudos Pharm Ltd SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
ES2548353T3 (en) * 2006-12-28 2015-10-15 Abbvie Inc. Poly (ADP-ribose) polymerase inhibitors
US20100249112A1 (en) 2007-05-25 2010-09-30 Astrazeneca R&D Combination of chk and parp inhibitors for the treatment of cancers
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
EP2220073B1 (en) * 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
UY31603A1 (en) 2008-01-23 2009-08-31 DERIVATIVES OF FTALAZINONA
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
JP2013532683A (en) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド Substituted 4- (4-fluoro-3- (piperazin-1-carbonyl) benzyl) phthalazin-1 (2H) -one derivatives as poly (ADP ribose) polymerase-1 inhibitors
CN102372716A (en) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 Phthalazone derivative, its preparation method and application in medicine thereof
CN102372706A (en) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 Phthalazinone derivative, its preparation method and application in medicament
CN102372698A (en) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 Phthalazinone derivative and its preparation method and use in medicine
JP5699223B2 (en) * 2010-12-02 2015-04-08 シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド Heterocyclic derivatives, their synthesis and medical applications
CN102485721B (en) 2010-12-03 2015-12-09 曹亚 2，3-benzodiazine ketone compound replaced and uses thereof
TWI577693B (en) 2011-05-31 2017-04-11 江蘇康緣藥業股份有限公司 Poly(ADP-ribose) polymerase tricyclic inhibitor
ES2562903T3 (en) 2011-07-13 2016-03-09 Santen Pharmaceutical Co., Ltd New compound that has PARP inhibitory activity
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
MX2014008071A (en) 2011-12-31 2015-07-06 Beigene Ltd Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors.
CN103242273B (en) 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-arylbenzofuran-7-methanamide compound, preparation method and application thereof
UA116627C2 (en) 2012-02-09 2018-04-25 Мерк Патент Гмбх Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014102817A1 *

Also Published As

Publication number Publication date
TWI553005B (en) 2016-10-11
DK2938598T3 (en) 2017-02-13
EA201591239A1 (en) 2015-10-30
IL238714A0 (en) 2015-07-01
HRP20170219T1 (en) 2017-04-07
WO2014102817A1 (en) 2014-07-03
CA2890309A1 (en) 2014-07-03
MA38080A1 (en) 2018-02-28
PH12015501199A1 (en) 2015-08-17
JP5930452B2 (en) 2016-06-08
ES2614885T3 (en) 2017-06-02
EP2938598B1 (en) 2016-12-21
AR094299A1 (en) 2015-07-22
CN104918917A (en) 2015-09-16
US20150291603A1 (en) 2015-10-15
PL2938598T3 (en) 2017-05-31
NZ708255A (en) 2016-08-26
MX2015006780A (en) 2015-08-06
HUE030613T2 (en) 2017-05-29
PH12015501199B1 (en) 2018-01-17
HK1210466A1 (en) 2016-04-22
BR112015012425A2 (en) 2017-07-11
CL2015001655A1 (en) 2015-10-02
AP2015008439A0 (en) 2015-05-31
CO7400872A2 (en) 2015-09-30
KR101652654B1 (en) 2016-08-30
AU2013368842A1 (en) 2015-05-21
SG11201503670YA (en) 2015-07-30
ZA201503218B (en) 2016-01-27
JP2016504347A (en) 2016-02-12
PT2938598T (en) 2017-02-07
GEP201706691B (en) 2017-06-26
US9598418B2 (en) 2017-03-21
AU2013368842B2 (en) 2015-11-12
KR20150091137A (en) 2015-08-07
TW201441219A (en) 2014-11-01

Similar Documents

Publication Publication Date Title
EP2938598B1 (en) Substituted phthalazin-1(2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
CN109328187B (en) Novel compound with FGFR (FGFR) inhibitory activity as well as preparation and application thereof
JP6832430B2 (en) Inhibitors of cell metabolism
EP3423435B1 (en) Substituted indole mcl-1 inhibitors
EP1942900B1 (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases
US20240208912A1 (en) MTA-Cooperative PRMT5 Inhibitors
EP2598491B1 (en) Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN113166156B (en) Tyrosine kinase inhibitors, compositions and methods
KR20080074963A (en) Imidazopyrazine as a Protein Kinase Inhibitor
KR20210153051A (en) macrocyclic compounds
WO2023091726A1 (en) Inhibitors of cyclin‑dependent kinase 12 (cdk12)
CN104744446A (en) Hetero-aromatic compound and application thereof in medicine
EP4313308A1 (en) Tead inhibitors and uses thereof
CN111153891B (en) Substituted benzimidazole PI3K alpha/mTOR double-target inhibitor and pharmaceutical composition and application thereof
CN104640862B (en) Novel heteroaryl and heterocycle compounds, composition and methods thereof
OA17331A (en) Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADPribose) polymerase-1.
HK1210466B (en) Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
KR20230171440A (en) pharmaceutical compound
HK40051544A (en) Tyrosine kinase inhibitors, compositions and methods there of
HK1221421A1 (en) Antiproliferative compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210466

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160803

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 4

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 855343

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170115

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20161222

Year of fee payment: 4

Ref country code: IE

Payment date: 20161227

Year of fee payment: 4

Ref country code: DK

Payment date: 20161221

Year of fee payment: 4

Ref country code: NL

Payment date: 20161221

Year of fee payment: 4

Ref country code: LU

Payment date: 20161227

Year of fee payment: 4

Ref country code: CH

Payment date: 20161221

Year of fee payment: 4

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013015746

Country of ref document: DE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2938598

Country of ref document: PT

Date of ref document: 20170207

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20170126

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20170219

Country of ref document: HR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20170207

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20161221

Year of fee payment: 4

Ref country code: ES

Payment date: 20161222

Year of fee payment: 4

Ref country code: FR

Payment date: 20161222

Year of fee payment: 4

Ref country code: SE

Payment date: 20161221

Year of fee payment: 4

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170219

Country of ref document: HR

Payment date: 20170313

Year of fee payment: 4

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20161221

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20170219

Country of ref document: HR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20170208

Year of fee payment: 4

Ref country code: DE

Payment date: 20161222

Year of fee payment: 4

Ref country code: NO

Payment date: 20170113

Year of fee payment: 4

Ref country code: RO

Payment date: 20161228

Year of fee payment: 4

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E030613

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20170206

Year of fee payment: 4

Ref country code: CZ

Payment date: 20170220

Year of fee payment: 4

Ref country code: HR

Payment date: 20170313

Year of fee payment: 4

Ref country code: PL

Payment date: 20161227

Year of fee payment: 4

Ref country code: HU

Payment date: 20161230

Year of fee payment: 4

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2614885

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170602

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20170217

Year of fee payment: 4

Ref country code: IT

Payment date: 20161231

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20161223

Year of fee payment: 4

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013015746

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1210466

Country of ref document: HK

26N No opposition filed

Effective date: 20170922

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20170219

Country of ref document: HR

Effective date: 20171223

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013015746

Country of ref document: DE

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20171231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20180101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20171223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171224

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161223

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180101

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180831

REG Reference to a national code

Ref country code: BE

Ref legal event code: FP

Effective date: 20170222

Ref country code: BE

Ref legal event code: MM

Effective date: 20171231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171224

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180924

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180102

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180705

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180706

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 855343

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161221

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20190702

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171224

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 855343

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171223